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Abstract 
 
Introduction: Mesenchymal stem cells (MSCs) have therapeutic potential for 
myocardial infarctions, yet their recruitment to injured myocardium is poor. Optimising 
their endothelial adhesion may improve their recruitment to such myocardium. 
Pretreating haematopoietic stem cells with inflammatory cytokines or hydrogen 
peroxide (H2O2) improves their endothelial adhesion. I therefore tested whether such 
pretreatment of MSCs enhances their adhesion to cardiovascular endothelium. 
Methods: Primary murine (mMSCs) or human (hMSCs) MSCs were incubated with 
cytokines or H2O2 and their adhesion to murine cardiac endothelial cells (MuCEC), 
human coronary artery endothelial cells (HCAECs) and murine heart sections 
determined. Results: Pre-treating mMSCs (passage 7-9) with H2O2 and IFNγ 
significantly increased their adhesion to MuCEC. However, the effect of H2O2 was lost 
when higher passage mMSCs (passage 10) were used. hMSC adhesion to HCAEC 
significantly increased with SDF-1α and IL-8 pre-treatment. Adhesion of mMSCs to 
healthy heart sections was significantly decreased by mMSC pretreatment with H2O2 , 
murine IL-8 and SDF-1α. Conclusion: This study indicates that cytokine/H2O2 
pretreatment of MSCs can improve their cardiac endothelial adhesion, but not their 
adhesion to naïve cardiac sections. Interestingly, the species of MSC origin, cell 
passage number and the adhesive surface used influenced the manner in which 
adhesion was altered. 
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1. Literature Review 
 
1.1 Introduction/Overview 
 
Cardiovascular disease (CVD), the chronic burden of which is increasing, has 
significant societal and personal costs. Inadequate healing of myocardial infarctions 
(MIs) and the subsequent development of chronic CVD is a major contributor to this 
burden. Mesenchymal stem cells (MSCs) are nonhaematopoietic stromal cells 
possessing multilineage potential. They are capable of differentiating into 
osteoblasts, chondrocytes, adipocytes and myoblasts (1). MSCs have the potential to 
augment post-MI myocardial repair via their cytoprotective, proangiogenic, 
proarteriogenic, inotropic and immunomodulatory properties. Clinical studies have 
shown MSCs to have therapeutic merit for cardiac disease. However, the recruitment 
of systemically-delivered MSCs to sites of ischaemic injury is poor. Optimising MSC 
adhesion to endothelium may improve their homing to such injured tissues, thus 
potentially enhancing their therapeutic benefits. Our lab has previously increased 
haematopoietic stem cell (HSC) adhesion to injured gut and kidney (in vitro and in 
vivo), by pre-treating HSCs with inflammatory cytokines or hydrogen peroxide (H2O2). 
We therefore tested whether such strategies could improve MSC adhesion to cardiac 
endothelium and murine heart sections. 
 
 
 
1.2 MSC Characterisation 
 
The minimal criteria for the definition of human MSCs (hMSCs) are: adherence to 
plastic in culture, a phenotype which is positive for the surface antigens CD105, 
CD73, CD90 and negative for CD45, CD34, CD14/CD11b, CD79α/CD19 and HLA- 
DR. They must also be capable of in vitro differentiation into osteoblasts, adipocytes 
and chondroblasts (2). This is thought to represent the best current definition of a 
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hMSC. Murine MSCs express different surface epitopes to hMSCs. A recent study 
characterised the surface markers of conditionally immortalised mMSCs by flow 
cytometry, identifying CD9, CD24, CD29, CD44, CD47, CD49e, CD98 CD81, VCAM- 
1, CD138, CD147, Cr11 and Sca1 as highly expressed on the cell surface (3). 
However, expression of surface markers has been found to differ between various 
mouse strains (4). 
 
 
 
1.3 Myocardial Infarction and Chronic Disease Burden 
 
Myocardial necrosis that is consistent with myocardial ischaemia constitutes an MI. 
An MI is most often caused by underlying coronary atherosclerosis (5). 7 % of US 
adults have coronary heart disease (CHD), with an MI prevalence of 4.3 % for men 
and 2.2 % for women (6). Despite this considerable MI disease burden, community 
surveillance studies of MI outcomes show a recent decline in the severity of MI and in 
its fatality rate, particularly among younger individuals (6,7). However, the incidence 
of heart failure — one complication of MI — is increasing (8).This phenomenon has 
been attributed to an ageing population and the falling MI fatality rate (9). Con- 
sequently, the optimisation of post-infarct myocardial healing is desirable, in order to 
prevent or ameliorate complications of an infarcted myocardium. 
 
 
 
The long-term repair of a myocardial infarct is both adaptive (e.g. weakened necrotic 
tissue, which predisposes the myocardium to rupture is eventually replaced by scar 
tissue) and maladaptive (e.g. ventricular dilation and distortion, impaired cardiac 
perfomance) (10). The post-infarct inflammatory milieu is an important driver of 
myocardial repair and has many interconnected elements. These include the initiation 
of a cytokine cascade, complement activation, reactive oxygen species (ROS) 
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production and neutrophils migration to the site of injury (11). Within the healing heart 
there exists a balance between pro-inflammatory and anti-inflammatory elements. 
Myocardial mast cell numbers increase during MI healing. Mast cell-derived 
histamine, tryptase, TGF-β, bFGF and VEGF promote fibroblast proliferation, type 1 
collagen production and angiogenesis – all essential components of myocardial 
repair (11). Optimising these responses presents a considerable challenge. However, 
as the following discussion demonstrates, MSCs have the potential to augment 
myocardial repair via their cytoprotective, proangiogenic, proarteriogenic, inotropic 
and immunomodulatory properties. 
 
 
 
1.4  MSC Homing to Sites of Tissue Injury 
 
 
 
In vitro evidence suggests that MSCs preferentially adhere to injured tissue. Aldridge 
et al. showed significantly increased adhesion of hMSCs to sections of diseased and 
healthy human liver. This adhesion appears to be CD29 and CD44 dependent (12). 
In vivo evidence points to widespread MSC homing to and engraftment in injured 
tissues. Lung engraftment of bleomycin-resistant MSCs is increased 23-fold in 
bleomycin-induced lung injury (13). Human adipose-derived MSCs implant into the 
intestine of in rats with radiation induced intestinal injury – no homing of hAd-MSCs is 
observed in normal intestine (14). Focused irradiation (abdominal and hind limb) 
considerably increases MSC engraftment at the irradiated site (15). 
 
There is substantial evidence that these observations of MSC homing to injured 
tissue are replicated in heart. Interpretation of some studies is complicated by the 
use of bone marrow mononuclear cell (BMMC)/bone marrow derived stem cell 
(BMDSC) populations, which are likely to contain haematopoietic and mesenchymal 
subpopulations. Strong evidence exists that such mixed populations home to and are 
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retained by IR injured hearts (16,17). However, these studies do not reflect the 
homing capacity of MSCs alone. Several studies have described homing of MSC 
populations to injured heart. In one such study, canine MSCs were administered 
intravenously 72 hours post-MI. Initial MSC uptake was primarily to the lung, in a 
perfusion-dependent manner. At 24 hours post-MSC injection, MSC redistribution to 
the heart was increased in infarcted hearts compared to controls (18). Despite this, 
the MSCs that engrafted in the injured heart represented a small proportion of those 
which had been injected. Freyman et al. administered MSCs to pigs 15 minutes post- 
MI, via intravenous (IV), endocardial (EC), intracoronary (IC) routes. No sham 
surgery or MSC placebo controls were used. At 14 days IV MSCs were not 
detectable within the infarcts. For the IC and EC routes, retention was 6 % and 3 % 
respectively (19). Several studies have shown cardiac uptake of IV-administered (20) 
and intraventricularly-administerd (21) MSCs to be significantly greater in infarcted 
hearts compared to sham-operated controls. Furthermore, intraventricular 
administration of MSCs significantly decreases lung uptake compared to IV 
administration and increases myocardial uptake of the cells (21). Others have 
presented compelling visual evidence for MSC engraftment in MI zones (although no 
quantification of this observation is provided) (22). 
 
In summary, there is strong evidence for preferential uptake of MSCs to infarcted 
heart, although this uptake is small in absolute terms, particularly if MSCS are 
administered IV. 
 
1.5 Mechanisms of MSC Homing to Injured Myocardium 
 
 
 
In order to enhance the homing of MSCs to injured myocardium, the mechanisms 
underlying this homing must be established. It is conceptually useful to divide the 
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mediators of MSC homing into: (1) the cytokines/chemokines which attract MSCs 
bearing corresponding receptors to the site of injury and (2) the adhesion molecules 
which allow this chemotactic attraction to manifest as MSC rolling, adhesion and 
transmigration. 
 
The act of haematopoeitic stem cell (HSC) homing is well described as a sequence 
of selectin-mediated rolling, integrin-mediated adhesion and transmigration (23). 
MSCs appear to home in a similar manner. In vitro and in vivo assays of MSC 
behaviour have demonstrated extension of podia as well as rolling and firm adhesion 
behaviour (23). Rolling can be induced on immmobilised P-selectin and inhibited by 
anti P-selectin antibodies. Additionally, endothelial anti-VCAM-1 and MSC anti-VLA-4 
treatment impair MSC binding to human umbilical vein endothelial cells (HUVEC) 
(23). Thus MSCs undergo a series of homing steps similar to those observed in 
HSCs (26) (Fig. 1.1). 
 
 
 
 
 
 
Figure 1.1. Mechanism of MSC homing along a chemokine gradient. MSC rolling is selectin-mediated, with CD44 
implicated as the principal ligand (MSC expression of PSGL-1 and ESL-1 is low). Firm endothelial adhesion of MSCs is 
mediated by the integrins and selectins. VCAM-1-VLA-4 interactions allow transendothelial MSC migration. Adapted 
from: Salem HK. Stem Cells 2010;28:585–596. 
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There exist many chemokine receptor-ligand pairs which might play a role in MSC 
chemotaxis to injured myocardium. Such relationships have been comprehensively 
characterised by microarray profiling of ischaemically injured mouse hearts, 
combined with FACS/RT-PCR analysis of MSCs (25). These findings are well 
summarised in a review by Wu et al. (Fig. 1.2) (26). Although some differences exist 
between mMSCs and hMSCs, their receptor profile is largely similar (26). 
 
 
 
 
 
 
 
 
Figure 1.2. MSC chemokine receptors and their ligands. Ligands whose ex- 
pression has been shown to be upregulated in ischaemic myocardium are shown 
in red. Expression of those in yellow has not been investigated. Adapted from Wu 
Y, Zhao RCH. Stem Cell Rev and Rep 2012;8:243–250. 
 
 
 
 
 
 
It is evident from Fig. 1.2 that considerable scope remains for investigating the 
expression of chemokine receptors and ligands in MI. The relative importance of 
each chemokine/ligand pair in MSC homing is also of interest but has not been fully 
characterised. This information could allow focused enhancement of MSC homing. In 
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vitro, hMSCs migrate most prominently in response to PDGF-AB and IGF-1. CCL5, 
SDF-1 and CCL22 (formerly MDC) have a minor effect, although this is enhanced by 
pre-incubation of MSCs with TNFα which increases MSC CCR2, CCR3 and CCR4 
expression. (27). Integrin β1 but not CXCR4 blockade causes a significant reduction 
in MSC recruitment to a myocardial infarct (26). However, the MSCs in this particular 
study were used at passages 4-5, at which stage CXCR4 expression is known to 
decline (26). Schenk et al. merged measurements of post-MI myocardial chemokine 
expression and MSC chemokine receptor expression. CCL3 (Formerly MCP-3), a 
CCR1/CCR2 ligand, was implicated as an important MSC homing agent. When 
CCL3 was overexpressed 1 month post-infarct, MSC homing to the heart was 
restored (28). In murine IR-injured hearts, CCL2 (MCP-1)-CCR2 interactions have 
also been implicated as important for the significant increase in MSC homing to 
infarct border zones (29). 
 
1.6  Clinical Studies of MSC Treatment in Cardiac Disease 
 
 
 
Given the considerable evidence that MSCs home to IR injured heart, it is important to 
establish whether they are capable of producing a therapeutic benefit. In pigs, 
transepicardial injection of MSCs into IR-injured myocardium prevents a further 
decline in left ventricular ejection fraction (LVEF) (30,31) and improves blood flow in 
infarct and border zones (31). Such improvements have also been observed in sheep 
(32). Transendocardial injection of MSCs has been similarly successful. MSC 
injection in pigs 3 days post-MI has been shown to limit the surface area and depth of 
myocardial scar formation (33). Furthermore, at 8 weeks following treatment, cardiac 
function improved in the pigs receiving MSCs whereas the systolic and diastolic 
function of the control group declined (33). Other animal studies of transendocardial 
MSC injection have confirmed these findings and have also demonstrated an MSC- 
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induced improvement in myocardial blood flow, capillary density and ischaemic area 
 
(34,35). 
 
 
 
IV administration of MSCs is complicated by their lung entrapment and low 
engraftment in the heart. Some clinical benefit has been described. In one study IV 
injection of MSCs 15 minutes post cardiac reperfusion in pigs improved the end 
systolic pressure-volume and preload-stroke work relationships at 12 weeks – 
without an improvement in LVEF (36). No improvements in scar thickness/size, 
vessel density, left ventricular end diastolic pressure (LVEDP), left ventricular systolic 
pressure (LVSP) were been observed (36), although a study in rats has described 
significant improvements in these outcomes (22). These are parameters which are 
consistently improve with intramyocardial MSC injection (see above). Another study 
in pigs has described IV-MSC induced improvements in LVEF and wall thickening at 
 
12 weeks post MI (37). However, the magnitude of this LVEF improvement was not 
large, and may not represent a clinically meaningful increase. 
 
MSC treatment has been trialled clinically in post-MI patients and in those with 
ischaemic cardiomyopathy/LV dysfunction. One study showed that IC injection of 
autologous MSCs within 12 hours of MI increased ventricular wall movement velocity 
at the site of infarction at 3 months, decreased perfusion defects and improved LVEF 
(38). Another recent study reported no change in LVEF with transendocardial 
autologous MSC treatment, although these patients had ischaemic cardiomyopathy, 
rather than a recent MI. Interestingly, their performance on a 6-minute walk test 
improved with MSC treatment (40). The recently published POSEIDON trial 
examined allogeneic and autologous transendocardial MSC injection in those with LV 
dysfunction. MSCs reduced mean end diastolic elastance, but there was no increase 
in EF. Despite this, autologous MSCS produced a significant improvement in the 6- 
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minute walk test and quality of life. Neither MSC treatment improved exercise VO2max 
(40). One major trial has examined IV administration of (allogeneic) MSCs. The 
treatment improved subjective symptom scores, but not the 6-minute walk test. 
Baseline LVEF was similar in both groups. There was a modest MSC-mediated 
increase in LVEF at 6 months compared to post-MI baseline. Animal and human 
studies consistently demonstrate a therapeutic benefit with post-MI MSC therapy, 
however the optimal mode and timing of administration remain to be clarified. 
 
1.7 MSC-Mediated Healing in Cardiac Disease 
 
 
Evidence suggests that MSCs differentiate into cardiac cells, albeit in low numbers. 
Even with intramyocardial injection, only ~0.44 % of MSCs remain within healthy 
myocardium at 4 days (41). However, MSCs that remain in healthy and infarcted 
myocardium beyond 1 week assume a cardiomyocyte morphology; 
immunohistochemistry reveals de novo expression of desmin, β-myosin heavy chain, 
α actinin, cardiac troponin T and phospholamban (41,42). MSC participation in 
coronary angiogenesis has been shown in a swine and canine models of ischaemic 
cardiomyopathy (34,43). 
 
Given that MSC retention within the heart is poor, other mechanisms are likely to 
contribute to their clinical benefit. MSCs release a wide range of cytokines, growth 
factors and chemokines which may promote adaptive cardiac remodelling. These in- 
clude adrenomedullin, angiogenin, angiopoetin-1, fibroblast growth factors (FGFs), 
insulin-like growth factor-1(IGF-1), maxtric metalloproteinases and VEGF (44). Inject- 
ing conditioned medium from MSCs overexpressing Akt into post-MI rat hearts re- 
duces infarct size and improves LV function (45,46). Genes expressing VEGF, IGF-1 
and FGF-2 are upregulated in these MSCs. Bone marrow mononuclear cell super- 
natants contain VEGF, IL-1β, PDGF, and IGF-1. Intramyocardial injection of these su- 
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pernatants significantly improves post-infarct microvessel density, decreases fibrotic 
area and improves cardiac function (47). In summary, MSCs release factors which 
promote extracellular matrix growth, and which have cytoprotective, proangiogenic, 
proarteriogenic and inotropic properties (44,48). 
 
 
 
MSCs also have immunomodulatory potential. The importance of the post-MI 
inflammatory response to adaptive and maladaptive cardiac remodelling is outlined in 
section 1.3. In traumatic brain injury models, MSC administration reduces 
macrophage and leukocyte infiltration to the injured tissue, levels of pro-inflammatory 
cytokines are also reduced and levels of anti-inflammatory cytokines increased (49). 
MSC prostaglandin E2 release in sepsis promotes anti-inflammatory IL-10 release 
from macrophages and confers a survival benefit (50). Intramyocardial bone marrow- 
derived progenitor cell (BM-MNC) injection into infarcted myocardium induces IL-10 
dependent improvements in cardiac function; improvements have not been observed 
with IL-10 knockout BM-MNCs (51). It is likely that MSCs exert some of their 
therapeutic effect in an immunomodulatory fashion. 
 
 
 
1.8  Improving MSC Homing 
 
 
 
Given the strong evidence that MSCs improve myocardial healing and the evidence 
for their poor retention in the heart, developing strategies to enhance MSC 
recruitment to injured myocardium is vital. Furthermore, IV injection of MSCs is 
desirable; intramyocardial injection is invasive. In order for such injections to be 
clinically viable, MSC recruitment to injured heart must be improved. The paracrine 
as well as transdifferention actions of MSCs are likely to be enhanced by MSC 
localisation at the site of injury. Chemical/cytokine pretreatment of MSCs is one 
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avenue of exploration. Others, such as genetic modification of MSCs to increase their 
expression of adhesion molecules are beyond the scope of this discussion. 
 
The chemokine receptor-ligand pairs which appear to be most important in 
chemotactic MSC homing to IR injured heart are discussed in section 1.5, along with 
the mediators of endothelial MSC rolling and transmigration. This physiological 
response to injury may be exploited in order to enhance MSC recruitment. Our lab 
has successfully increased in vitro and in vivo HSC adherence to IR injured kidney 
and intestine by pretreating the cells with SDF-1α, keratinocyte chemokine (KC) and 
H2O2 (52–54).The underlying mechanism appears to be increased cell surface 
clustering of integrins, resulting in enhanced integrin-ligand affinity and avidity (52– 
54). MSCs appear to respond to such priming in a similar fashion. Pretreating MSCs 
with a cytokine cocktail (Flt-3 ligand, stem cell factor [SCF], IL-6, hepatocyte growth 
factor [HGF] and IL-3) has been shown to increase cell surface expression of 
CXCR4. Functionally, this resulted in increased MSC homing to SDF-1 and the bone 
marrow of sub-lethally irradiated mice (55). Prenatal transplantation of SDF-1α- 
pretreated fetal blood MSCs increases CXCR4 cell surface expression and promotes 
bone MSC engraftment (56). In vitro, TNFα pretreatment of MSCs can improve their 
homing towards chemokines; this is accompanied by increased cell surface 
expression of CCR2, CCR3 and CCR4, but not CXCR4 (27). Pretreating MSCs with 
IL-1β may promote their intestinal homing in a murine colitis model, via increased cell 
surface expression of CXCR4. Murine colitis treatment with such MSCs improved 
survival, attenuated weight-loss and reduced the histopathological severity of the 
disease compared with untreated MSCs (57). It is clear that priming MSCs with 
cytokines has the potential to improve their homing to IR injured hearts, but evidence 
is as yet limited. Segers et al. pretreated cardiac microvascular endothelium (CMVE) 
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and aortic endothelium (AE) with cytokines, demonstrating the well-described 
increase in MSC adherence to TNFα-activated endothelium (58). However, when 
both endothelium and MSCs were treated with TNFα, there was no additive effect. 
The authors also report treating MSCs with other cytokines (e.g. IL-1β, SDF-1α, IL-3), 
but their observations of the resulting endothelial MSC adhesion are not reported. 
Segers et al. also showed that intraventricular injection of TNFα-pretreated MSCs 
increases their retention in uninjured heart 3-fold. Although abundant MSC 
accumulation in infarcted tissue is reported, the effect of TNFα pretreatment on MSC 
accumulation in these injured tissues is not stated (58). Futhermore, the potential 
therapeutic benefit of administering cytokine-pretreated MSCs to IR injured hearts is 
not addressed in this study. 
 
In summary, it is clear that MSCs can augment post-MI myocardial repair. However, 
their homing to injured myocardium is sub-optimal. Our lab has demonstrated 
increased HSC adhesion to injured gut and kidney, by pre-treating HSCs with 
inflammatory cytokines or hydrogen peroxide (H2O2). Others have presented 
evidence that cytokine treatment of MSCs increases their chemokine receptor 
expression and homing towards chemokines. No study has adequately examined 
whether cytokine/H2O2 pretreatment of MSCs enhances their adhesion to 
cardiovascular endothelium, their homing to IR-injured heart or their therapeutic 
benefit in MI. The work described in this thesis explores whether cytokine 
pretreatment of MSCs improves their in vitro adhesion to cardiac endothelium and 
murine cardiac sections. 
 
1.9  Hypothesis and Aims 
 
 
 
The evidence outlined above clearly demonstrates the therapeutic potential of MSCs 
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in MI. It also shows that cytokine pretreatment of MSCs has the potential to improve 
their homing to injury sites and their endothelial adhesion. No study has adequately 
examined the effects of such pretreament on MSC adhesion to cardiovascular 
endothelium. Furthermore, H2O2 pretreatment of HSCs promotes increased integrin 
clustering at the cell surface, thus improving HSC endothelial adhesion and retention 
in ischaemically-injured organs. We therefore hypothesised that: 
 
1.  Cytokine and H2O2 pretreatment of murine and human MSCs would improve 
their static adhesion to cardiac endothelium. 
 
2.  Cytokine and H2O2 pretreatment of murine MSCs would improve their static 
adhesion to murine cardiac sections. 
 
This work aimed to: 
 
 
 
1.  Determine whether pretreatment of murine MSCs with cytokines/H2O2 alters 
their adhesion to murine cardiac endothelium. 
 
2.  Investigate whether pretreatment of human MSCs with cytokines/H2O2 alters 
their adhesion to human coronary artery endothelium. 
 
3.  Establish whether pretreatment of murine MSCs with cytokines/H2O2 alters 
their adhesion to murine cardiac sections. 
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2. Methods 
 
 
 
All materials were obtained from Sigma-Aldrich, St. Louis, MO, USA unless otherwise 
stated. 
 
2.1  Cell Culture 
 
 
 
2.1.1  Murine Cardiac Endothelial Cells 
 
 
 
Immortalised mouse cardiac endothelial cells (MuCEC, obtained from Dr. Elaine 
Lidington, Imperial College School of Medicine, UK), were cultured in T75 cell culture 
flasks, each containing 15mL Dulbecco's Modified Eagle Medium supplemented with 
10 % fetal bovine serum (FBS), 100μg/mL penicillin/streptomycin (PS), 2mM L- 
glutamine, 10 ng/mL murine epidermal growth factor (mEGF). The cells were 
incubated at 37 °C, 5 % CO2. Cells were fed every 2-3 days and subcultured (1:4) 
when 90 % confluent. 
 
Subcultivation was carried out under sterile conditions in a class II safety cabinet. The 
spent culture media was aspirated and the vessel washed once with PBS. The cells 
were enzymatically dissociated using 7 mL of 3x trypsin. 7 mL of serum- containing 
medium was added to the flask. The contents of the flask were centrifuged at 300 g, 
21 °C for 10 minutes. The supernatant was removed and the pellet resuspended in 
media. The cell suspension was split into culture flasks containing 14 mL of 
prewarmed (37 °C) media. The flasks were incubated at 37 °C, 5 % CO2. 
 
2.1.2  Murine Mesenchymal Stem Cells 
 
 
 
Cells were isolated from mouse bone marrow according to the procedure described 
by Houlihan et. al. (20). Briefly, the cells were isolated from the tibia and femora of 
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C57Bl/6 mice. These bones were isolated, crushed with a pestle and mortar and 
incubated with collegenase-containing DMEM. The cell suspension was filtered and 
the erythrocytes lysed. The suspension was then incubated with allophycocyanin 
(APC)-conjugated PDGFR-α, FITC-conjugated Sca-1, phycoerythrin (PE)-conjugated 
CD45 and Ter119. The MSC (PDGFR-α+ Sca-1+ CD45- Ter119-) population was 
isolated by flow cytometry. The MSCs were transferred to a cell culture plate 
containing 2mL Minimum Essential Medium Eagle (MEM) supplemented with 10 % 
FBS, 100μg/mL penicillin/streptomycin (PS), 2mM L-glutamine, 10 ng/mL 
transforming growth factor β (complete MEM) and incubated at 37 °C, 5 % CO2. They 
were subcultured at 90 % confluence. 
 
Subsequent passages were grown in T75 culture flasks, each containing 15 mL 
complete MEM and were incubated at 37°C, 5 % CO2. They were fed every 2-3 days 
and subcultured (1:3), according to the protocol described in section 2.1.1. The 
MSCs were used between passages 7 and 10 (inclusive). 
 
 
 
2.1.3  Human Coronary Artery Endothelial Cells 
 
 
 
Human coronary artery endothelial cells (HCAECs, PromoCell, Heidelberg, 
Germany) were cultured at at 37 °C, 5 % CO2 in T75 flasks containing 14 mL growth 
medium (Endothelial Cell Growth Medium, Promocell, Heidelberg, Germany). The 
HCAECs were fed every 2-3 days and subcultured (1:3) at 90 % confluence (see 
Section 2.1.1). 
 
2.1.4  Human Mesenchymal Stem Cells 
 
 
 
hMSCs (Lonza, MD, USA) cultured at at 37 °C, 5 % CO2 in T75 flasks containing 14 
mL Mesenchymal Stem Cell Basal Medium (MSCBM), (Lonza, MD, USA), 
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supplemented with Mesenchymal Stem Cell Growth Supplement (MCGS) (Lonza, 
MD, USA). The hMSCs were fed every 2-3 days and subcultured (see Section 2.1.3) 
when 90 % confluent. 
 
2.2  Static Adhesion Assays 
 
 
 
2.2.1  Static Adhesion Assay – Murine Mesenchymal Stem Cells and Murine 
 
Cardiac Endothelial Cells. 
 
 
 
Static adhesion assays were repeated in triplicate. Initially, MSCs (passages 7-9) 
were pretreated with variety of cytokine/chemical solutions (TNFα, IL-1β, IFNγ, KC 
and SDF-1α, at 100 ng/mL,100 μM H2O2, MEM control). Additional assays used MSC 
(passage 10) pretreatment with a range of H2O2 concentraions (MEM control, 1 μM, 
10 μM, 100 μM, 500μM, 1 mM). H2O2 treatment solutions were freshly prepared for 
each experiment, to mitigate the effect of H2O2 decomposition. 
 
200 μL of sterile 2 % gelatin was pipetted into each well of a 24-well plate and 
incubated at 37 °C, 5% CO2 for 30 minutes. MuCECs were dissociated from their 
culture flask (see Section 2.1.1) and the pellet resuspended in DMEM. Gelatin which 
had not adhered to the plate was aspirated from the wells. 500μL of cell suspension 
was added to each well. The plate was incubated at 37 °C, 5 % CO2. 
 
Once the MuCECs had grown to confluence, the medium was removed and each 
well washed twice with PBS. 500 μL of complete MEM, containing TNFα at 100 
ng/mL was added to each well and incubated for 4 hours at 37 °C, 5 % CO2. One well 
was not treated with TNFα – 500 μL of complete MEM was added to this well. MSC 
treatment solutions were prepared (see above). MSCs were dissociated from their 
culture flask and centrifuged as described in section 2.1.2. They were resuspended in 
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1 μL CFSE/1 mL PBS and incubated at 37 °C, 5 % CO2 for 15 minutes. 1 mL of 
complete MEM was added and the cells centrifuged at 300 g 21 °C for 10 minutes. 
The MSCs were resuspended in 2 mL of PBS. 20μL of the suspension was retained 
for cell counting and the remaining sample was centrifuged as before. The resulting 
pellet was resuspended in MEM. 1x105 cells were added to each of 8 eppendorfs. 
The cells were centrifuged as before and each pellet resuspended in 1 mL of 
treatment solution. Each eppendorf was then incubated for 1 hour at 37 °C. The cell 
suspensions were again centrifuged and the pellet resuspended in PBS. MEM was 
aspirated from the 24-well plate and it was washed 3 times with PBS. 500 μL of 
treated cell suspension (5x104 cells) was added to each well and the plate incubated 
at 37 °C for 20 minutes. The wells were washed gently with PBS twice and then 350 
μL of formalin was added to each. The plate was incubated for 15 minutes at room 
temperature. The wells were washed once with PBS and if not imaged immediately, 
stored at 4 °C in the dark, with 500 μL of PBS in each well. 
 
The plate was imaged at 10x magnification on a digital inverted fluorescence 
microscope (EVOS fl, Fischer Scientific, Waltham, MA, USA). 5 views of each well 
were obtained. The first field of view was taken at the centre of each well, with 
subsequent fields obtained by moving just beyond the limit of the last field, in a 
predefined pattern. The cells in each field were counted using a blinded cell counting 
program. 
 
2.2.2  Static Adhesion Assay – Human Mesenchymal Stem Cells and Human 
 
Coronary Artery Endothelial Cells. 
 
 
 
Again, static adhesion assays were repeated in triplicate. hMSCs (passages 2-3) 
 
were pretreated with variety of cytokine/chemical solutions (TNFα, IFNγ, SDFα, IL-8, 
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IL-6 at 100 ng/mL, 100 μM  H2O2 and an MSCBM control) and their adhesion to a 
confluent HCAEC monolayer quantified. Endothelial Cell Growth Medium was used 
during the endothelial activation step. MSCBM medium was used for hMSC 
incubations. The procedure was otherwise as described in section 2.2.1. 
 
2.3  Stamper-Woodruff Assay 
 
 
 
Stamper-Woodruff assays were carried out to examine the adherence of mMSCs 
(passage 10), pretreated with variety of cytokine/chemical solutions to murine heart 
sections. The treatments were TNFα, IL-1β, IFNγ, KC, SDFα at 100ng/mL, 100 μM 
H2O2 and an MEM control. Sham hearts were excised, placed in liquid nitrogen and 
stored at -80 °C. The hearts were cryosectioned, the sections transferred to glass 
slides, fixed in acetone for 20 minutes, allowed to air-dry and then stored at -20 °C. 
 
MSCs were CFSE labelled and treated as described in section 2.2.1. Slides were 
brought to room temperature and re-fixed in acetone for 5 minutes. Once dry, each 
section was washed gently three times. A hydrophobic pen (ImmEdge, Vector 
Laboratories, Peterborough, UK) was used to draw a barrier around each section. 
5x104 MSCs in 100 μL MEM were added to each section and incubated at room 
temperature, in the dark, for 20 minutes. The sections were washed three times as 
before, fixed in acetone for 5 minutes and washed again. A water based mounting 
medium (Hydromount, National Diagnostics, Atlanta, GA, USA) was dropped onto 
each section and a coverslip applied. Slides were left to dry in the dark overnight at 
room temperature), then stored at 4 °C. 
 
The sections were imaged at 10x magnification on a digital inverted fluorescence 
microscope. 5 views of each section (placed on the stage with its long axis 
horizontal, apex of the heart on the right) were obtained. The first field of view was 
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taken at the lower leftmost point of the section with subsequent fields obtained by 
moving just beyond the limit of the last field, in a predefined pattern. The cells in each 
field were counted using a blinded cell counting program. 
 
2.4  Statistical Analysis 
 
 
 
Shapiro-Wilk tests of normality were carried out on all data groups. Transformation of 
non-normal data was considered inappropriate, given the small sample sizes. Data 
was analysed by Kruskal Wallis tests, with post-hoc Mann-Whitney U analysis (IBM 
SPSS Statistics 21). 
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3. Results 
 
 
 
3.1  Murine Static Adhesion Assay – Cytokine and H2O2 Treatments 
 
 
 
The median values for each group are presented along with maximum, minimum and 
interquartile range (IQR) values (Table 3.1). The Shapiro-Wilk test demonstrated 
significant deviation from normality in 6 of the 8 treatment groups (i.e. p < 0.05) 
(Table 3.2). As the data is largely non-parametric, it is presented in the box and 
whisker plot format, to allow the reader to appreciate its spread (Fig. 3.1). 
Considerable inter-group and intra-group variation in cell counts per field of view can 
be seen. The data is also presented in the more conventional bar chart format (Fig. 
3.2). A significant increase in MSC adhesion to cardiac endothelium was observed 
with H2O2 (p < 0.0001) and IFNγ (p = 0.04) pretreatment of the MSCs (Fig. 3.2). 
Representative fluorescent microscopy images demonstrate the H2O2-induced 
increase in MSC adhesion to a confluent cardiac endothelial monolayer (Fig. 3.3). 
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Table 3.1. Descriptive statistics for the static adhesion of pretreated murine 
mesenchymal stem cells (mMSCs) to murine cardiac endothelium (MuCEC). 
MMSCs (passage 7-9) were CFSE labelled, then pretreated for 1 hour with a cytokine 
(100 ng/mL), H2O2  (100 μM) or medium alone (control). Treated mMSCs were 
incubated for 20 minutes with TNFα-activated confluent MuCEC monolayers on a 24- 
well plate (5x104 cells/well). mMSC adhesion was systematically assessed at 10x 
magnification using a fluorescence microscope. NEA = no endothelial activation with 
TNFα, KC = keratinocyte chemokine, IQR = interquartile range. n=3, 5 observations 
per experiment. 
 
 Minimum Median IQR Maximum 
 (cells/field of view) 
Control 0 25 19 49 
NEA 4 19 77 574 
TNFα 3 47 77 389 
IL-1β 2 8 26 62 
IFNγ 6 36 34 65 
KC 0 23 139 226 
SDF-1α 8 29 112 185 
H2O2 14 69 100 254 
 
 
 
 
Table 3.2. Shapiro-Wilk test of normality for observations of pretreated 
murine mesenchymal stem cell (mMSC) adhesion to murine cardiac 
endothelium (MuCEC). mMSCs (passage 7-9) were CFSE labelled, then 
pretreated for 1 hour with a cytokine (100 ng/mL), H2O2  (100 μM) or medium 
alone (control). Treated mMSCs were incubated for 20 minutes with TNFα- 
activated confluent MuCEC monolayers on a 24-well plate (5x104 cells/well). 
mMSC adhesion was systematically assessed at 10x magnification using a 
fluorescence microscope. n=3, 5 observations per experiment. 
 
 
 Statistic N Sig.* 
Control .950 15 .517 
NEA .597 15 .000 
TNFα .673 15 .000 
IL-1β .796 15 .003 
IFNγ .941 15 .389 
KC .784 15 .002 
SDF-1α .779 15 .002 
H2O2 .874 15 .039 
*p<0.05 
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Figure 3.1. Static adhesion of pretreated murine mesenchymal stem cells 
(mMSCs) to murine cardiac endothelium (MuCEC). mMSCs (passage 7-9) were 
CFSE labelled, then pretreated for 1 hour with a cytokine (100 ng/mL), H2O2  (100 μM) 
or medium alone (control). Treated mMSCs were incubated for 20 minutes with TNFα- 
activated confluent MuCEC monolayers on a 24-well plate (5x104 cells/well). mMSC 
adhesion was systematically assessed at 10x magnification using a fluorescence mi- 
croscope. n=3, 5 observations per experiment. NEA = no endothelial activation,KC = 
keratinocyte chemokine. Black line denotes median value. Boxes = interquartile range 
(IQR). Bars = highest/lowest datum within 1.5IQR of upper/lower quartile. ° = outlier 
>1.5IQR of upper/lower quartile but < 3 box lengths from upper end of box. * = ex- 
treme outlier > 3 box lengths from upper end of box. 
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Figure 3.2. Effect of pretreatment on the static adhesion of murine mesen 
chymal stem cells (mMSCs) to murine cardiac endothelium (MuCEC). mMSCs (pas- 
sage 7-9) were CFSE labelled, then pretreated for 1 hour with a cytokine (100 ng/mL), 
H2O2  (100 μM) or medium alone (control). Treated mMSCs were incubated for 20 minutes 
with TNFα-activated confluent MuCEC monolayers on a 24-well plate (5x104 cells/well). 
mMSC adhesion was systematically assessed at 10x magnification using a fluorescence 
microscope. Data presented as mean ±SEM. n=3, 5 observations per experiment. NEA = 
no endothelial activationKC = keratinocyte chemokine. * = p<0.05, *** = p<0.001 vs. con- 
trol. 
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Figure 3.3. Effect of H2O2 pretreatment on murine mesenchymal stem cell (mMSC) static adhesion to a 
confluent murine cardiac endothelial (MuCEC) monolayer – representative images. mMSCs (passage 7-9) 
were CFSE labelled, then pretreated for 1 hour with 100 μM H2O2   or medium alone (control). Treated MSCs 
were incubated for 20 minutes with confluent MuCEC monolayers on a 24-well plate (5x104 cells/well). MSC ad- 
hesion was systematically assessed at 10x magnification using a fluorescence microscope. (A) control; (B) 100 
μM H2O2. 
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3.2  Murine Static Adhesion Assay – Various H2O2 Concentrations 
 
 
 
The median cell count per field of view values for each group are detailed, along with 
the maximum value, minimum value and the IQR (Table 3.3). Shapiro-Wilk tests 
demonstrated a deviation from normality in 4 of the 6 treatment groups (table 3.4). 
Again, considerable within-group variation in cell count per field of view values can 
be appreciated; for this reason the data is presented in the box and whisker plot as 
well as the bar chart format (Fig. 3.4, Fig. 3.5). No significant difference was detected 
between the groups (Fig. 3.5). 100 μM H2O2 pretreatment of MSCs (Fig. 3.5) did not 
increase their endothelial adhesion, despite our earlier observations to the contrary 
(Fig. 3.2). We had hoped to perform Annexin V/Propidium iodide flow cytometry to 
determine MSC viability with H2O2 treatment. This was not possible in the time 
available. Haemocytometer counts of live/dead cells by trypan blue staining did not 
reveal any obvious increase in cell death with H2O2 treatments up to 1 mM (Table 
3.5). 
25  
Table 3.3. Descriptive statistics for the static adhesion of H2O2-treated murine 
mesenchymal stem cells (mMSCs) to murine cardiac endothelium (MuCEC). 
mMSCs (passage 10) were CFSE labelled, then pretreated for 1 hour with H2O2  or 
medium alone (control). Treated mMSCs were incubated for 20 minutes with TNFα- 
activated confluent MuCEC monolayers on a 24-well plate (5x104 cells/well). MSC 
adhesion was systematically assessed at 10x magnification using a fluorescence 
microscope. n=3, 5 observations per experiment. IQR = interquartile range 
 
Minimum Median IQR Maximum 
Cell count/field of view 
 
Control 6 28 74 110 
1μM 14 30 23 69 
10μM 12 36 58 95 
100μM 17 42 62 157 
500μM 5 46 51 118 
1mM 18 40 89 137 
 
 
 
 
 
 
 
Table 3.4. Shapiro-Wilk test of normality for observations of pretreated 
murine mesenchymal stem cell (mMSC) adhesion to murine cardiac 
endothelium (MuCEC). mMSCs (passage 10) were CFSE labelled, then 
pretreated for 1 hour with H2O2  or medium alone (control). Treated mMSCs 
were incubated for 20 minutes with TNFα-activated confluent MuCEC 
monolayers on a 24-well plate (5x104 cells/well). mMSC adhesion was 
systematically assessed at 10x magnification using a fluorescence 
microscope. n=3, 5 observations per experiment. 
 
        Statistic N Sig.*  
Control .845 15 .015 
1μM .915 15 .162 
10μM .869 15 .033 
100μM .837 15 .011 
500μM .945 15 .444 
1mM .792 15 .003 
*p<0.05 
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Table 3.5. Murine mesenchymal stem cell (mMSC) viability after H2O2 treatment. 
mMSCs were treated with H2O2  or medium alone (control) for 1 hour. The cells were centri- 
fuged and the pellet resuspended in medium (100,000 cells/mL medium). 20 μL of cell sus- 
pension was diluted 1:1 with trypan blue. The total number of live and dead cells in 4 
haemocytomer corner squares was counted. n=3, data presented is mean of the three ex- 
periments performed. 
 
 Live (cells) Dead (cells) % Dead 
Control 16.0 6.8 42.5 
1 μM 9.0 3.3 27.0 
10 μM 9.3 5.0 34.9 
100 μM 15.7 4.3 21.7 
500 μM 14.7 10.7 42.1 
1 mM 20.0 9.7 32.6 
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Figure 3.4. Static adhesion of H2O2 pretreated murine mesenchymal stem 
cells (mMSCs) to murine cardiac endothelium (MuCEC). mMSCs (passage 
10) were CFSE labelled, then pretreated for 1 hour with H2O2  or medium alone 
(control). Treated mMSCs were incubated for 20 minutes with confluent 
MuCEC monolayers on a 24-well plate (5x104 cells/well). mMSC adhesion was 
systematically assessed at 10x magnification using a fluorescence micro- 
scope. n=3, 5 observations per experiment. Black line denotes median value. 
Boxes = interquartile range (IQR). Bars = highest/lowest datum within 1.5IQR 
of upper/lower quartile. ° = outlier >1.5IQR of upper/lower quartile but < 3 box 
lengths from upper end of box. 
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Figure 3.5. Effect of H2O2 pretreatment on the static adhesion of murine 
mesenchymal stem cells (mMSCs) to murine cardiac endothelium 
(MuCEC). mMSCs (passage 10) were CFSE labelled, then pretreated for 1 
hour with H2O2 or medium alone (control). Treated mMSCs were incubated for 
20 minutes with TNFα-activated confluent MuCEC monolayers on a 24-well 
plate (5x104 cells/well). mMSC adhesion was systematically assessed at 10x 
magnification using a fluorescence microscope. Data presented as mean 
±SEM. n=3, 5 observations per experiment. 
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3.3  Human Static Adhesion Assay 
 
 
The median cell count per field of view values for each group are detailed, along with 
the maximum value, minimum value and the IQR (Table 3.6). The data was normally 
distributed in 6 of 8 groups (Table 3.7). Given this, use of parametric statistical tests 
was considered. However, the variances between groups were not equal (Levene’s 
test significance < 0.0001), thus violating another assumption of ANOVA. Non- 
parametric statistical analysis was retained. 
 
Prominent intra and inter-group differences in cell counts are evident when the data 
is visualised on a box and whisker plot (Fig 3.6). Pretreating MSCs with SDF-1α and 
IL-8 significantly increased their adhesion to HCAECs (p = 0.034, p = 0.029 
respectively). Representative fluorescent microscopy images demonstrate the SDF- 
1α-induced increase in MSC adhesion to HCAECs (Fig. 3.8). Cells within a confluent 
HCAEC monolayer were observed to be less densely packed than those in a MuCEC 
monolayer (Fig.3.3, Fig. 3.8). 
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Table 3.6. Descriptive statistics for the static adhesion of pretreated human 
mesenchymal stem cells (hMSCs) to human cardiac endothelium (HCAEC). 
hMSCs (passage 2-3) were CFSE labelled, then pretreated for 1 hour with a cytokine 
(100 ng/mL), H2O2  (100 μM) or medium alone (control). Treated hMSCs were incubated 
for 20 minutes with confluent TNFα-activated HCAEC monolayers on a 24-well plate 
(5x104 cells/well). hMSC adhesion was systematically assessed at 10x magnification 
using a fluorescence microscope.  IQR = interquartile range, NEA = no endothelial 
activation. n=3, 5 observations per experiment. 
 
 
 Minimum Median IQR Maximum 
Control 5 12 22 42 
NEA 5 26 26 65 
TNFα 8 30 25 50 
SDF-1α 8 32 37 81 
IL-8 10 21 36 83 
IL-6 7 17 15 31 
IFNγ 3 13 13 41 
H2O2 2 9 13 24 
 
 
 
 
 
Table 3.7. Shapiro-Wilk test of normality for observations of 
pretreated human mesenchymal stem cell (hMSC) adhesion to 
human coronary artery endothelium (HCAEC). hMSCs (passage 2-3) 
were CFSE labelled, then pretreated for 1 hour with a cytokine (100 
ng/mL), H2O2  (100 μM) or medium alone (control). Treated hMSCs were 
incubated for 20 minutes with TNFα-activated confluent HCAEC 
monolayers on a 24-well plate (5x104 cells/well). hMSC adhesion was 
systematically assessed at 10x magnification using a fluorescence 
microscope. NEA = no endothelial activation n=3, 5 observations per 
experiment. 
 
 Statistic N Sig.* 
Control .870 15 .034 
NEA .917 15 .172 
TNFα .946 15 .465 
SDF-1α .894 15 .076 
IL-8 .860 15 .024 
IL-6 .932 15 .297 
IFNγ .917 15 .176 
H2O2 .918 15 .179 
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Figure 3.6. Static adhesion of pretreated human mesenchymal stem cells 
(hMSCs) to human cardiac endothelium (HCAEC). hMSCs (passage 2-3) were 
CFSE labelled, then pretreated for 1 hour with a cytokine (100 ng/mL), H2O2  (100 
μM) or medium alone (control). Treated hMSCs were incubated for 20 minutes 
with TNFα-activated ,confluent HCAEC monolayers on a 24-well plate (5x104 
cells/well). hMSC adhesion was systematically assessed at 10x magnification us- 
ing a fluorescence microscope. NEA = no endothelial activation. n=3, 5 observa- 
tions per experiment. Black line denotes median value. Boxes = interquartile 
range (IQR). Bars = highest/lowest datum within 1.5IQR of upper/lower quartile. ° 
= outlier >1.5IQR of upper/lower quartile but < 3 box lengths from upper end of 
box. 
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Figure 3.7. Effect of pretreatment on the static adhesion of human mesen- 
chymal stem cells (hMSCs) to human cardiac endothelium (HCAEC). hMSCs 
(passage 2-3) were CFSE labelled, then pretreated for 1 hour with a cytokine (100 
ng/mL), H2O2  (100 μM) or medium alone (control). Treated hMSCs were incubated 
for 20 minutes with TNFα-activated, confluent HCAEC monolayers on a 24-well 
plate (5x104 cells/well). hMSC adhesion was systematically assessed at 10x magni- 
fication using a fluorescence microscope. NEA = no endothelial activation. Data 
presented as mean ±SEM. n=3, 5 observations per experiment. chemokine. * = 
p<0.05 vs. control. 
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Figure 3.8. Effect of SDF-1α pretreatment on human mesenchymal stem cell (hMSC) static adhesion to a 
confluent human cardiac endothelial (HCAEC) monolayer – representative images. hMSCs (passage 2-3) 
were CFSE labelled, then pretreated for 1 hour with SDF-1α (100 ng/mL) or medium alone (control). Treated 
hMSCs were incubated for 20 minutes with confluent HCAEC monolayers on a 24-well plate (5x104 cells/well). 
hMSC adhesion was systematically assessed at 10x magnification using a fluorescence microscope. (A) control; 
(B) SDF-1α. 
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3.4  Stamper-Woodruff Assay. 
 
 
 
As in previous sections, the median cell count per field of view values for each group 
are detailed, along with the maximum value, minimum value and the IQR (Table 3.8). 
The data was non-parametric in all groups (Table 3.9). The non-normal spread of 
data is evident on a box and whisker plot, with outlying data points featuring 
prominently (Fig. 3.9). Representative fluorescence microscopy images illustrate the 
considerable variation in numbers of adherent mMSCs in the TNFα-treated group 
(Fig. 3.11, panels A-C). Fewer MSCs adhered to murine heart sections per field of 
view (mean 10.2 cells) compared to a MuCEC monolayer (mean 51 cells) (Fig. 3.1, 
3.2, 3.4, 3.5 3.9, 3.10). MSC adherence to murine cardiac sections was significantly 
decreased by H2O2 (p = 0.001), KC (p = 0.026) and SDF-1α (p = 0.046) (Fig. 3.10). 
Notably, in some fields of view, across all treatment conditions, MSCs were observed 
to cluster at the intraventricular endothelial/endocardial surfaces (Fig. 3.11, panels D- 
F). 
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Table 3.8. Descriptive statistics for the adhesion of pretreated murine 
mesenchymal stem cells (mMSCs) to murine cardiac sections. mMSCs (passage 
10) were CFSE labelled, then pretreated for 1 hour with a cytokine (100 ng/mL), H2O2 
(100 μM) or medium alone (control). Treated mMSCs were incubated for 20 minutes 
with acetone-fixed murine cardiac sections (5x104 cells/section). mMSC adhesion was 
systematically assessed at 10x magnification using a fluorescence microscope. n=4, 
5 observations per experiment. IQR = interquartile range. 
 
 Minimum Median IQR Maximum 
Control 2 9 14 117 
TNFα 0 9 6.5 120 
IL-1β 1 6 8 25 
IFNγ 1 5.5 11 51 
KC 0 4.5 13.75 35 
SDF-1α 0 6.5 9.5 60 
H2O2 (100μM) 0 5 4.75 38 
 
 
 
 
 
 
Table 3.9. Shapiro-Wilk test on observations of pretreated murine 
mesenchymal stem cell (mMSC) adhesion to murine cardiac sections. 
mMSCs (passage 10) were CFSE labelled, then pretreated for 1 hour with a 
cytokine (100 ng/mL), H2O2  (100 μM) or medium alone (control). Treated 
mMSCs were incubated for 20 minutes with acetone-fixed murine cardiac 
sections (5x104 cells/section). hMSC adhesion was systematically assessed at 
10x magnification using a fluorescence microscope. n=3, 5 observations per 
experiment. 
 
 Statistic N Sig.* 
Control .575 40 .000 
TNFα .463 40 .000 
IL-1β .905 40 .003 
IFNγ .715 40 .000 
KC .835 40 .000 
SDF-1α .703 40 .000 
H2O2 .692 40 .000 
*p<0.05 
34  
Ce
ll 
co
un
t 
pe
r 
fie
ld
 o
f v
ie
w
 
 
 
Figure 3.9. Adhesion of pretreated murine mesenchymal stem cells (mMSCs) 
to murine cardiac sections. mMSCs (passage 10) were CFSE labelled, then pre- 
treated for 1 hour with a cytokine (100 ng/mL), H2O2  (100 μM) or medium alone 
(control). Treated mMSCs were incubated for 20 minutes with acetone-fixed murine 
cardiac sections (5x104 cells/section). mMSC adhesion was systematically as- 
sessed at 10x magnification using a fluorescence microscope. n=4, 5 observations 
per experiment. KC = keratinocyte chemokine. Black line denotes median value. 
Boxes = interquartile range (IQR). Bars = highest/lowest datum within 1.5IQR of up- 
per/lower quartile. ° = outlier >1.5IQR of upper/lower quartile but < 3 box lengths 
from upper end of box. * = extreme outlier > 3 box lengths from upper end of box. 
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Figure 3.10. Effect of pretreatment on the static adhesion of murine mesen- 
chymal stem cells (mMSCs) to murine cardiac sections. mMSCs (passage 
10) were CFSE labelled, then pretreated for 1 hour with a cytokine (100 ng/mL), 
H2O2  (100 μM) or medium alone (control). Treated mMSCs were incubated for 20 
minutes with acetone-fixed murine cardiac sections (5x104 cells/section). mMSC 
adhesion was systematically assessed at 10x magnification using a fluorescence 
microscope. n=4, 5 observations per experiment. KC = keratinocyte chemokine.* 
= p<0.05, *** = p<0.001 vs. control. 
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Figure 3.11. Representative fluorescence images of murine mesen- 
chymal stem cell (mMSC) adhesion to murine cardiac sections. 
mMSCs (passage 10) were CFSE-labelled, then pretreated for 1 hour with 
cytokines/H2O2  or medium alone (control). Treated mMSCs were incubated 
for 20 minutes with acetone-fixed murine cardiac sections (5x104 cells/sec- 
tion). mMSC adhesion was visualised at 10x magnification using a fluores- 
cence microscope. (A,B,C) = images illustrating the variability in TNF-α- 
treated mMSC adherence to cardiac sections. (D,E,F) Endothelial/endocar- 
dial clustering of MSCs. 
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4. Discussion 
 
 
 
4.1  Enhancing MSC Adhesion to Murine Cardiac Endothelium. 
 
 
 
Pretreatment of mMSCs with H2O2 and IFNγ significantly increased their adhesion to 
a confluent MuCEC monolayer, with H2O2 producing a 4.3-fold increase in MSC 
adhesion (Fig. 3.2). Previous evidence from our lab has shown H2O2 to increase HSC 
adhesion to IR injured kidney and intestine. Furthermore, a H2O2-mediated increase 
in cell surface integrin clustering has been shown to mediate this enhanced adhesion 
(52–54). Such clustering is known to enhance integrin binding avidity (59). This is the 
first time H2O2 has been shown to promote MSC adhesion to endothelium. Further 
study is required to determine whether the mechanisms responsible for this 
enhanced adhesion are similar in MSCs and HSCs. IFNγ increased MSC adhesion to 
MuCEC 1.4-fold. Treatment of MSCs with IFNγ has previously been shown to 
increase their cell surface expression of ICAM-1 and VCAM-1 (60), possibly 
explaining the increase in adhesion to MuCEC observed here. Furthermore, 
expression of these adhesion molecules is important for MSC-mediated 
immunoregulation (60), raising the possibility that IFNγ pretreatment of MSCs may 
enhance their immunomodulatory potential in the heart. As outlined in section 1, MSC 
pretreatment with SDF-1α, TNFα and IL-1β has previously shown chemotactic 
promise (27,56,57), yet no significant increase in MSC adhesion to MuCEC was 
found here. This may appear surprising, given the considerably greater mean cell 
count values obtained for SDF-1α, TNFα and IL-1β, compared to IFNγ (Fig. 3.2). 
However, it must be remembered that the Kruskal-Wallis one-way analysis of 
variance is based on ranked data. That the changes in cell count induced by SDF-1α, 
TNFα and IL-1β were statistically insignificant can be better appreciated by 
examining the data spread (Fig. 3.1). The number of assays completed was limited 
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by time constraints and the number of MSCs which were available. Given the large 
standard error which appears inherent to the assay (Fig. 3.1, Fig 3.2) a greater 
number of assays may demonstrate a significant effect of KC, SDF-1α and TNFα. I 
suggest that the standard deviation values derived from this data will be useful in 
designing future experiments with sufficient numbers to detect a meaningful change 
in adhesion. 
 
Given the pronounced effect of H2O2 discussed above, a range of H2O2 concentrations 
were then used for MSC pretreatment, to establish whether there was a dose-
response effect on adhesion to MuCEC. Contrary to expectations, the 100 μM H2O2-
mediated increase in MSC adherence to MuCEC was not reproduced, and 
none of the additional concentrations had a significant effect (Fig. 3.5). In the earlier 
experiments discussed above, MSCs were used between passages 7-9. It was 
necessary to use the MSCs in subsequent experiments at passage 10. A passage- 
related decline in MSC surface receptor expression is well described. CXCR4 
expression declines beyond passages 4-5 (26). Honczarenko et al. demonstrated a 
marked decline in MSC cell surface chemokine expression at passages 12-16, with 
an accompanying decrease in the expression of adhesion molecules such as ICAM- 
1, ICAM-2 and VCAM-1. As a result, passage 16 MSCs did not display chemotactic 
responses in vitro (61). It is possible that such alterations in surface protein 
expression underlie the failure of H2O2 to alter MSC adhesion to MuCEC at passage 
10. Further work should aim to characterise passage-related alterations in such 
expression, in parallel with alterations in MSC adhesion. This is of vital clinical 
relevance. To date, IV-administered MSCs have been used before passage 5 in 
human clinical trials, largely due to concerns about their tumorigenic potential at later 
passages (62–64). It may be that MSCs are also clinically less effective at later 
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passages. I suggest that their passage-related adhesive properties be fully 
characterised and that future work be carried out at clinically relevant passages. 
 
It is possible that H2O2 treatment of MSCs alters cell viability. Only adherent, viable 
cells are of therapeutic relevance. A FACS Annexin V/Propidium Iodide apoptosis 
assay was planned. However, the limited availability of MSCs within the time-frame of 
this project prevented its completion. Trypan blue staining counts of live/ dead cells 
are presented in section 3.2. It appears that H2O2 pretreatment of MSCs up to 1 mM 
does not enhance cell death. 
 
4.2 Enhancing MSC Adhesion to Human Coronary Artery Endothelium. 
 
 
 
Pretreatment of passage 2 and 3 hMSCs (clinically relevant passages; see above) 
with SDF-1α and IL-8 significantly increased their adhesion to confluent HCAEC 
monolayers. TNFα, IL-6, IFNγ, and H2O2 did not modify MSC adhesion to HCAEC. 
There is an apparent trend towards TNFα increasing hMSC adhesion to HCAEC (Fig. 
3.7), but this did not reach significance (p = 0.059). As with the experiments 
described in section 4.1, the number assays was limited by the quantity of MSCs 
which could be generated in the time available. Again, this work would benefit from 
additional assays being completed, and from this data being used to design 
experiments with sufficient numbers to detect relevant changes in MSC adhesion. 
 
SDF-1α is known to enhance hMSC chemotactic homing in vitro and in vivo, 
apparently via inducing increased MSC surface expression of CXCR4 (27,56). The 
effect of SDF-1α and IL-8 on hMSC integrin activation (critical for endothelial 
adhesion and transmigration of MSCs) is less well characterised. SDF-1α and IL-8 
may increase adhesion of hMSCs to VCAM-1 in a parallel plate flow chamber, 
although the underlying mechanism has not been characterised (65). It is possible 
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that increased hMSC expression and/or clustering of α4β1 integrin underlies this 
increase in adhesion. Importantly, Ciuculescu et al. highlighted considerable inter- 
donor variability in hMSC response to chemokine stimulation. SDF-1α increased 
hMSC adhesion to VCAM-1 in 2/5 MSC donors, IL-8 significantly enhanced such 
adhesion in 1/5 donors (65). Thus, it may be that a broad chemokine cocktail would 
provide the best opportunity for enhancing endothelial adhesion of autologous MSCs 
in a clinical context. Alternatively, a reliable method of in vitro MSC screening may 
allow individualised pretreatment of MSCs. We used a commercially available 
primary hMSC product. Our results are therefore representative of the MSC donors 
used to generate that product. In order to generate an accurate picture of the 
aggregate response of hMSCs to cytokine/ H2O2 priming, it may be necessary to 
assess such treatments in MSCs from multiple, defined donors. 
 
Although TNFα pretreated MSCs did not display significantly increased adherence to 
HCAEC, a trend was evident. It is plausible that further investigation might reveal a 
significant effect. In vitro and in vivo homing of rat MSCs is enhanced by 
preincubation with TNFα (66,67). The underlying mechanisms are unclear. Some 
describe an increase in MSC VCAM-1 expression, without alterations in ICAM-1, 
VLA-4 and L-selectin expression (66). Others have shown a TNFα-induced increase 
in MSC ICAM-1 expression, with no alteration in VCAM-1 expression (67). Segers et 
al. showed that TNFα pretreatment of rodent MSCs significantly increases their 
adhesion to coronary microvascular endothelium (CMVE). Furthermore, this 
adhesion was dependent on VCAM-1 induction (but not induction of ICAM-1 or VLA- 
 
4) in both CMVE and MSCs (58). MSC VLA4 interactions with endothelial VCAM-1 
are traditionally described. However, this work suggests that MSC VCAM-1, not just 
VLA4, mediates their adhesion to endothelium. Although studies of TNFα pretreated 
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hMSCs are lacking, this evidence from rat MSCs indicates that TNFα does have the 
potential to enhance MSC endothelial adherence. Characterisation of the effects of 
TNFα pretreatment on hMSCs and their adhesion to endothelium is therefore 
warranted. 
 
100 µM H2O2 did not alter hMSC HCAEC adhesion. In the absence of mechanistic 
data, it is difficult to explain the difference between the mMSC and hMSC responses 
to H2O2. It may be that H2O2 pretreatment of hMSCs does not induce the increase in 
cell surface integrin clustering (seen in HSCs), which may occur in H2O2-reponsive 
mMSCs. Future research must characterise these mechanisms. 
 
4.3  MSC Adhesion to Murine Cardiac Sections 
 
 
 
MSC adherence to murine cardiac sections was considerably less than that to 
MuCEC. MSC adherence to murine cardiac sections was significantly decreased by 
H2O2, KC, and SDF-1α (0.58, 0.47 and 0.62-fold respectively). MSCs clustered at the 
intraventricular endothelial/endocardial surfaces in some fields of view, although this 
was not a universal phenomenon. 
 
The reduced overall adhesion of MSCs to cardiac sections, compared to a confluent 
endothelial monolayer may be explained by recent work that has shown no VCAM-1 
expression in adult cardiomyocytes; adult cardiac expression of VCAM-1 is restricted 
to the endocardium, heart valves and vascular endothelium (68) (Fig. 4.1). Given the 
majority of cardiac section area consists of cardiomyocytes, poor MSC adhesion 
(likely due to limited VLA-4-VCAM-1 interaction) is unsurprising. This poor adhesion 
may also be explained by passage-related changes in MSC adhesion capacity which 
are discussed above. The MSCs used in the Stamper-Woodruff assays were at 
passage 10, those used in the static adhesion assays were between passage 7 and 
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passage 9.  The persistence of VCAM-1 within the endocardium and vascular 
endothelium (Fig. 4.1), may explain the (unquantified) phenomenon of MSC 
clustering at intraventricular endothelial/endocardial surfaces in some sections (Fig. 
3.11). I propose that future Stamper-Woodruff assay sections should be chosen so 
that a comparable ventricular/endocardial area is represented on the sections used 
for each treatment condition. The sections could be counterstained to allow 
ventricular and vascular endothelium to be identified. The relative cardiomyocyte and 
endothelial distribution of adherent MSCs may then be quantified. Sectioning of 
murine heart to expose the ventricular endothelial surface area may better allow 
measurement of MSC adhesion potential to this surface. It is unclear whether poor 
MSC adherence to cardiomyocytes is of clinical concern. Endothelial VCAM-1- 
mediated adhesion and transmigration may be of principal concern for improving the 
myocardial uptake of IV-administered MSCs. It is however possible that poor MSC 
adhesion to myocardial sections indicates a propensity for poor intra-myocardial 
retention. This would be of concern in the intramyocardial and intracoronary injection 
of MSCs, as well as in their IV administration. Given the considerable retention of IV- 
administered MSCs in the lungs (18), exploration of the mechanisms underlying both 
cardiac MSC uptake and their intramyocardial retention is essential. 
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Figure 4.1.Distribution of cardiac VCAM-1 expression in murine heart. (A) Embryonic myocardium (B) Adult myocardium. 
From: Ponten A, et al. PLoS ONE 2013;8(12): e82403. 
 
 
 
 
 
 
 
 
It is surprising that H2O2, KC and SDF-1α reduced MSC adhesion to murine cardiac 
sections. This is difficult to explain when coupled with a significant increase in H2O2- 
pretreated MSC adhesion to MuCEC, along with accompanying trends towards an 
increase in KC and SDF-1α adhesion (Fig. 3.2). Explanation of this result is further 
complicated by the absence of accompanying mechanistic data. mMSCs should 
respond in a similar manner to the identical treatments across the two experiments. 
Two plausible explanations for this exist. Firstly, the adhesive capabilites of the MSCs 
used in the Stamper-Woodruff assays may be impaired due to their late passage 
(passage 10, see discussion above) in comparison to those used in the equivalent 
static adhesion assay (passage 7-9). Secondly, the dominant mechanism mediating 
their adhesion to VCAM-1 deficient cardiac sections may differ from that mediating 
their adhesion to MuCEC. If this is the case, MSC pretreatment may have a different 
effect on their adhesion to cardiac sections. In any case, VCAM-1 is upregulated in 
adult heart following ischaemia-reperfusion injury (69), raising the possibility that 
MSC adhesion would be enhanced by cytokine/MSC pretreatment in such sections. 
This work was planned, but time constraints did not allow its completion. It is clear 
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that considerable further work is required to answer the questions raised here. Again, 
this data can inform this additional work, allowing robust study design with sufficient 
numbers to detect meaningful results. 
 
4.4 Concluding Remarks 
 
 
 
The pretreatment of MSCs with cytokines or H2O2 has the potential to improve their 
homing to injured myocardium. This work has provided a number of important 
insights into that potential. Firstly, there may exist an inter-species difference in the 
effectiveness of cytokines and H2O2 to improve MSC endothelial adherence; H2O2 
may not be an effective primer of hMSC adhesion. Secondly, the use of mMSCs at 
later, and therefore clinically irrelevant passages, may impair the ability of 
pretreatment to alter their adhesive properties. Caution should therefore be exercised 
in the interpretation of murine data and data derived from late-passage MSCs. 
Furthermore, the inter-donor differences in MSC response to individual cytokines 
must be borne in mind. A more complete examination of the response of hMSCs from 
clearly defined donors to cytokine priming is desirable. It is unclear whether the poor 
adhesion of mMSCs to cardiac sections is of clinical relevance. It may be that their 
endothelial adhesive properties are of greater importance for their uptake into injured 
myocardium. This should be explored further. This work is limited by the small 
sample sizes, but this data may be used to design powerful future experiments with 
adequate numbers to detect clinically meaningful changes in MSC adhesion. 
Discussion of this work is limited by our lack of knowledge of underlying mechanisms 
explaining the changes observed. Such mechanisms must be characterised. Finally, 
this in vitro work must be accompanied by in vivo studies of MSC homing to IR- 
injured myocardium and exploration of the functional consequences of improving 
such homing. 
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 Abstract 
 
Introduction: The vascular endothelial growth factor (VEGF) family may play a role 
in obesity and the metabolic syndrome. Placental growth factor (PlGF) is 
physiologically redundant, but pathologically important, making it an attractive anti- 
obesity target. We principally aimed to establish whether preadipocytes express PlGF 
and to explore the molecular regulation of PlGF and VEGF in murine preadipocytes. 
Methods: Preadipocytes were transfected with FoxO1-expressing adenoviruses and 
treated with H2O2, VEGF and cAMP. Adjunct work included quantification of PlGF 
secretion from endothelial-specific FoxO1,3,4 knockout livers and optimisation of 
preadipocyte differentiation to adipocytes.  Results: Wild-type FoxO1 transfection 
induced considerable increases in preadipocyte PlGF and VEGF expression. H2O2, 
VEGF, cAMP and forskolin treatments promoted an increase in preadipocyte FoxO1, 
VEGF and PlGF expression. Enhanced PlGF expression was not accompanied by an 
increase PlGF secretion. Conclusion: This is a preliminary exploration of the 
molecular regulation of PlGF in preadipocytes. Given the small sample sizes, the 
results should be interpreted cautiously. The mechanisms underlying our 
observations must be fully characterised. CREB promotion of Foxo1 and PlGF 
 
expression, along with SP-1 promotion of VEGF expression are of particular interest. 
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1. Literature Review / Introduction 
 
 
1.1 Introduction 
 
 
The vascular endothelial growth factors are a family of proteins traditionally 
associated with angiogenesis and vasculogenesis. However, many other 
physiological and pathophysiological functions of these proteins have emerged. 
Biological roles have been suggested for vascular endothelial growth factor (VEGF, 
also termed VEGF-A), VEGF-B and placental growth factor (PlGF) in the metabolic 
syndrome and its associated conditions. Notably, inhibition of PlGF and VEGF 
function has been shown to confer resistance to diet-induced obesity (DIO) (1–5). 
The physiological redundancy of PlGF makes it a particularly attractive anti-obesity 
target. Little is known about its molecular regulation, its cellular origins and its 
adipogenic importance within fat tissue. The work described in this thesis builds upon 
unpublished work from our lab, which characterised the molecular regulation of PlGF 
in human umbilical vein endothelial cells (HUVEC). Here we explore the molecular 
regulation of PlGF in murine preadipocytes. We establish whether such cells can 
produce PlGF and respond to stimulation with factors including hydrogen peroxide 
(H2O2), VEGF and cyclic AMP (cAMP). Secondary consideration is given to the 
molecular influences on VEGF expression in such cells. We also describe our efforts 
to optimise the differentiation of an established mouse preadipocyte cell line and 
primary preadipocytes to adipocytes. 
 
1.2 Vascular Endothelial Growth Factor Family – Structure. 
 
 
VEGF is the founding member of the VEGF family of proteins. It was first identified as 
a factor which increased vascular permeability (6–8). Its function as a vascular 
endothelial cell growth factor was subsequently discovered and the named VEGF 
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proposed. It is a dimeric, disulfide-linked, glycoprotein (9). Several VEGF isoforms of 
differing amino acid lengths are produced by a single VEGF gene, via alternative 
mRNA splicing. VEGF165 is the predominant human isoform, (VEGF164 is the murine 
equivalent)(10–12). Characterisation of VEGF protein structure allowed identification 
of a wider VEGF family. The VEGF family now includes VEGF, VEGF-B, VEGF-C, 
VEGF-D, VEGF-E, VEGF-F and PlGF. All share a core VEGF homology domain 
(9,11,13). In humans, PlGF exists in 4 isoforms, PlGF-1 (PlGF131), PlGF-2 (PlGF152), 
PlGF-3 (PlGF203), and PlGF-4 (PlGF224) (14). One PlGF isoform has been identified 
in mice – a 158 amino acid protein with 65% identity to human PlGF-2 (15). Human 
and murine VEGF-B exist in two isoforms, VEGF-B167 and VEGF-B186 (16). 
 
1.3 Vascular Endothelial Growth Factor Family Receptors 
 
 
The VEGF family of receptors are vascular endothelial growth factor receptor 1 
(VEGFR-1, also known as fms-like tyrosine kinase; Flt-1), VEGFR-2 (KDR, human; 
Flk-1, mouse), VEGFR-3, neuropilin-1 (NP-1) and neuropilin-2 (NP-2). Each VEGF 
family member has its own pattern of receptor interaction (Fig. 1.1). This short review 
focuses only on those receptors interacting with VEGF, PlGF and VEGF-B. 
 
VEGFR-1 and VEGFR-2 each have seven extracellular immunoglobulin domains, a 
single transmembrane domain and an intracellular tyrosine kinase domain (17,18). 
VEGFR-1 also exists in a soluble form (sflt-1) which may antagonise the biological 
activity of its ligands (16). NP-1 and NP-2 act as co-receptors (9). NP-1 enhances 
VEGF signalling through VEGFR-2, possibly via pre-existing VEGFR-2/NP-1 
complexes (19,20). VEGFR-1 is principally expressed on endothelial cells, however it 
is also found on osteoblasts, monocytes/macrophages, placental trophoblasts, renal 
mesangial cells and hematopoietic stem cells (HSCs) (11). VEGFR-2 in also primarily 
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expressed in endothelial cells, but has also been identified on neuronal cells, 
osteoblasts, megakaryocytes and HSCs (11). 
 
 
Figure 1.1. Vascular endothelial growth factor receptor 
interactions. For simplicity, this figure depicts only those 
interactions between VEGF, VEGF-B, PlGF and their corresponding 
receptors. 
 
 
There appears to be a physiological interdependence between the VEGFR-1, 
sVEGFR-1 and VEGFR-2 receptors. In endothelial cells, VEGFR-2 populations 
generally predominate, therefore VEGFR-1/VEGFR-2 heterodimers form at the 
expense of VEGFR-1 homodimers (21). These heterodimers may constitute up to 
50% of the total VEGF receptor complexes (22) and their formation favours VEGF 
 
signalling over that of VEGF-B or PlGF (Fig. 1.1). 
 
 
VEGF binds to VEGFR-1 and sVEGFR-1 with greater affinity than to VEGFR-2. Thus, 
sVEGFR-1 may prevent VEGF binding to VEGFR-2 (16)(23). Although VEGFR-1 
activation is not necessary or sufficient for angiogenesis, its activation (e.g. by PlGF) 
can transphosphorylate VEGFR-2 and therefore potentiate the angiogenic signalling 
of VEGF via VEGFR-2 (20,24,25). This further illustrates the complicated 
physiological interdependence of these receptors. 
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Discussion of intracellular VEGFR-1/VEGFR-2 signal transduction is not possible in 
this short review, beyond that which is necessary to understand PlGF expression 
(see Section 1.5). The reader is referred to a recent review on the subject (21). 
 
1.4 Major Biological Functions of the Vascular Endothelial Growth Factor 
 
Family 
 
 
1.4.1  PlGF 
 
 
Discussion of PlGF's role in the metabolic syndrome and associated conditions will 
be reserved for Section 1.6. 
 
Like VEGF, PlGF is pro-angiogenic and contributes to the growth, migration and 
survival of endothelial cells (23,24). PlGF can mobilise HSCs via their VEGFR-1 
receptors (25). Bone marrow transplantation from PlGF+/+   to PlGF-/- mice restores 
normal arteriogenesis in hindlimbs with an occluded femoral artery (26). Additionally, 
PlGF promotes the proliferation and contraction of vascular smooth muscle cells (27). 
Many other cellular activities are influenced by PlGF (see Fig. 1.2). 
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Figure 1.2. Major cellular effects of PlGF. From Dewerchin and 
Carmeliet. Cold Spring Harb Perspect Med 2012;2:a011056. 
 
 
 
 
Despite its widespread cellular influence, PlGF is largely redundant in a physiological 
sense. VEGF deficient embryos (VEGF -/-) are not viable (see Section 1.4.2) (28). 
However the same group have shown the development of PlGF -/- mice to be normal 
(29). Futhermore, Malik et al. have shown that sequestration of VEGF, VEGF-B and 
PlGF in neonatal and adult mice produces the same effects as when VEGF alone is 
neutralised (30). 
 
Although PlGF appears to be unnecessary for physiological homeostasis, its 
deficiency can impair biological responses to pathological challenges. Carmeliet et 
al. have shown that PlGF -/-  inhibits angiogenesis in the ischaemic retina (29). Such 
knockout (KO) also slows the healing of skin wounds and impairs collateral vessel 
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growth in response to femoral artery occlusion. Transplantation of wild-type (WT) 
 
bone-marrow rescues these pathological phenomena (29). 
 
 
Altering PlGF function has a disease-modifying effect in many pathologies (for a 
comprehensive review see (31)). Its limited physiological role restricts the side-effects 
produced by such manipulations. Serum PlGF levels, hepatic PlGF mRNA and 
hepatic PlGF are higher in patients with liver cirrhosis (32) and PlGF blockade 
attenuates the progression of CCL4-induced liver cirrhosis in mice (33)(44). PlGF 
may be proinflammatory in rheumatoid arthritits. The synovium of rheumatoid arthritis 
patients contains ~5 times the PlGF of the synovium of those with osteoarthritis. (34). 
In mice with collagen-induced/anti-collagen antibody-induced arthritis, 
pharmacological PlGF inhibition reduces the severity of disease (34). In some 
pathologies, enhancing PlGF function may have a therapeutic effect. Post-myocardial 
infarction (MI) systemic injection of a PlGF-expressing adenovirus to mice promotes 
cardiac angiogenesis and vessel enlargement and improves left ventricular 
performance (35). 
 
PlGF mRNA and protein levels often correlate with survival in malignancies (36). 
There is a good rationale for anti-PlGF therapy in malignancy; angiogenesis is 
essential for tumour growth and survival. Furthermore, PlGF promotes tumour vessel 
disorganisation. PlGF blockade reverses this disorganisation in murine hepatocellular 
carcinoma (51), which may improve tumour oxygenation and chemotherapeutic 
effectiveness (52). PlGF promotes leukaemia cell migration and thus possibly the 
clinical migration of malignancies (53). Rolny et al. showed that downregulation of 
PlGF promotes an M1-like tumour-associated macrophage phenotype (52) and thus 
a shift away from tumorigenic M2-like phenotype (43). 
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1.4.2  VEGF 
 
 
VEGF is principally known as a factor involved in angiogenesis and vasculogenesis. 
It promotes the growth and survival of endothelial cells, in addition to their sprouting 
and tube formation (16,36,37). VEGF is highly expressed in tissues which are 
developing new capillaries (38). VEGF deficient embryos (VEGF -/-) are not viable 
and display defective formation of embryonic and extra-embryonic vasculature (28). 
Muscle-specific VEGF -/- in adult mice causes a 48% reduction in gastrocnemius 
capillary density and a 61% reduction in cardiac capillary density (39). Cutaneous 
overexpression of VEGF induces angiogenesis and a predisposition to the 
development of a psoriasis-like condition (40). VEGF also upregulates the expression 
of endothelial nitric oxide (NO) synthase (eNOS) and NO production by endothelial 
cells, via VEGFR-2 and the protein kinase C (PKC) signalling pathway (41,42). VEGF 
promotes HSC mobilisation from bone marrow, bone growth and is a monocyte 
chemoattractant (16); this is consistent with the cellular distribution of VEGFR-1 and 
VEGFR-2. 
 
1.4.3  VEGF-B 
 
 
Recent research has shown VEGF-B to have an important role in the regulation of 
endothelial fatty acid transporter expression and thus fatty acid uptake (43). This will 
be discussed further in Section 1.7. 
 
The other biological functions of VEGF-B are not well described; however our 
knowledge of its biology has increased considerably in recent years. It is principally 
expressed in striated muscle, myocardium and brown fat (16). It appears to inhibit the 
expression of pro-apoptotic factors, and has shown promise as a neuroprotective 
agent (44,45). Like PlGF, VEGF-B doesn’t appear to be necessary for blood vessel 
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survival under normal conditions, but may be important for vessel survival under 
pathological conditions (46). In mice, a cardiomyocyte-specific VEGF-B transgene 
has been shown to increase the density of the cardiac vasculature. Furthermore, the 
transgene reduced infarct size following MI and partially protected left ventricular 
function (47). Recent progress in elucidating the biological actions of VEGF-B is likely 
to continue in the coming years. 
 
1.5 Molecular Regulation of PlGF Expression 
 
 
The molecular regulation of PlGF expression is not well characterised. VEGF is 
known to increase PlGF expression, acting via VEGFR-2, the mitogen activated 
protein kinase (MAPK) pathway and protein kinase C (PKC) (48,49). Treating human 
rheumatoid arthritis synovial fibroblasts with PI3k and NF-kB antagonists eliminates a 
15-(S)-HETE-mediated increase in PlGF expression (56). An NF-kB binding site has 
been identified in the PlGF promotor (51). Metal response element-binding 
transcription factor 1 (MTF-1) binds to the PlGF promotor region and can thus 
increase PlGF expression (52,53). Forkhead/winged helix transcription factor FoxD1 
(BF-2) is expressed in stromal cells of the embryonic renal cortex. In these cells, 
PlGF transcription is induced by BF-2 binding to a site in the PLGF regulatory region 
(54). Additionally, two cAMP response elements (CREs) have been identified in the 
PlGF promotor region (55). 
 
Unpublished work from our lab (Samir Sissaoui, PhD thesis) has characterised the 
transcriptional regulation of PlGF in HUVEC. This work shows that hyperglycaemia 
and oxidative stress inhibit PI3k/Akt phosphorylation; this promotes FOXO1 nuclear 
translocation and interaction with the PlGF promotor. PlGF release from HUVEC is 
therefore induced. Conversely, IGF-1 activates the PI3k/Akt pathway – 
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phosphorylating FOXO1 – causing it to be retained in the cytoplasm and thus 
preventing PlGF transcription. 
 
1.6 The Vascular Endothelial Growth Factor Family in the Metabolic 
 
Syndrome 
 
 
In recent years, possible roles for PlGF, VEGF and VEGF-B in the metabolic 
syndrome have emerged. The metabolic syndrome is an aggregation of factors which 
increase the risk of atherosclerotic vascular disease and type 2 diabetes mellitus. 
The factors which are often included in its definition are dyslipidaemia, hypertension, 
abnormal glucose homeostasis/insulin resistance and abdominal obesity (56). 
 
There is substantial evidence that PlGF promotes atherosclerotic development. High 
plasma PlGF levels are associated with an increased long-term risk of coronary heart 
disease (57) and plasma PlGF levels increase with the number of metabolic 
syndrome criteria met (58). Khurana et al. induced neointimal lesions in 
hypercholesterolaemic and normocholesterolaemic rabbits, then administered 
perivascular injections of adenoviruses encoding LacZ or murine PlGF-2. PlGF-2 
adenoviral administration significantly increased intimal thickening, macrophage 
accumulation, endothelial vascular cell adhesion molecule-1 (VCAM-1) expression 
and adventitial neovascularization in the hypercholesterolaemic rabbits, compared to 
their LacZ controls. The intima to media ratio was increased in PlGF-transfected 
normocholesterolaemic rabbits (59). Furthermore, in murine models of 
atherosclerosis, regular intraperitoneal injection of an anti-PlGF antibody reduces 
aortic atherosclerotic plaque size and inflammatory cell infiltration into the plaque 
(60). sVEGFR-1 cannot be used as a sink for PlGF in sVEGFR-1-/- mice. These mice 
display an increase in atherosclerotic plaque formation and macrophage infiltration 
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into plaques (61). Given the above evidence and work from our lab demonstrating 
that PlGF is under the transcriptional control of FOXO1, it is interesting that ablation 
of all endothelial FOXO transcription factors protects against murine aortic 
atherosclerosis (62). 
 
A metabolic role for VEGF-B has recently been discovered. VEGF-B-/- mice display 
impaired uptake of lipids into tissues in which VEGF-B it is usually highly expressed 
(mitochondria-enriched and fatty acid-metabolising tissues such as muscle, heart, 
brown adipose tissue) (43). The excess lipids instead accumulate in white adipose 
tissue. VEGF-B induces fatty acid transport proteins 3 and 4 (FATP3, FATP4) in 
endothelial cells. VEGF-B is co-expressed with mitochondrial genes. It may therefore 
couple fatty acid transport to metabolic demand for fatty acids (43). Given the role 
that excessive lipid accumulation is thought to play in skeletal muscle insulin 
resistance (63), VEGF-B may represent a new clinical target in the metabolic 
syndrome. 
 
The VEGF family may also be a useful therapeutic target in obesity. It has been 
known for some time that inhibiting adipose tissue vascular development reduces the 
size of fat depots (1,2). Some work has suggested that VEGFR-2, but not VEGFR-1 
blockade inhibits murine DIO (3) and diet-induced liver steatosis (33). Indeed, 
inducible repression of VEGF in mice confers resistance to DIO (4). These mice have 
reduced food efficiency (decreased body weight [BW] gain per unit of caloric intake) 
and express brown adipocytes in gonadal white adipose tissue (gWAT) depots. 
Additionally, they display increased expression of brown adipose tissue specific 
genes, VEGF-B and FATPs in gWAT. Thus when VEGF is inhibited, WAT acquires 
the ability to take up fatty acids and metabolise them in an uncoupled fashion, with 
resulting protection against DIO. 
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Despite findings that VEGFR-1 blockade does not inhibit murine DIO, evidence for a 
 
PlGF role in adipogenesis and obesity exists. In male mice fed a high-fat (HF) diet for 
 
18 weeks, PlGF-/- lowered BW compared to wild-type (WT) controls (5). Additionally, 
blood vessel density was significantly lower in the PlGF-/-  mice compared to controls. 
Transplantation of PlGF-/-  bone marrow to WT mice decreased vessel density, along 
with a trend towards a decrease in BW and adipose depot size (5). A similar study by 
the same group, in which HF feeding was restricted to 3 weeks, failed to replicate 
these results (64). BW, individual fat pad sizes and blood vessel density were 
unaffected by PlGF-/-. The authors also report that PlGF-/-preadipocytes differentiate 
normally and that PlGF neutralising antibodies/recombinant PlGF have no effect on 
3T3-F442A preadipocyte differentiation into adipocytes (64). A further study from the 
same group, examined the effect of short-term (< 3 weeks) HF feeding in gravid/non- 
gravid, PlGF-/-/WT female mice (65). The non-gravid PlGF-/- mice did not differ from 
their WT controls in terms of BW, individual fat pad sizes and blood vessel density. 
The pregnant PlGF-/- mice did display reduced adipose tissue blood vessel density 
and fewer UCP-1 positive adipocytes in white adipose tissue depots (65). 
 
It is unclear whether PlGF plays an important role in adipogenesis; some have found 
VEGFR-1 blockade to be ineffective at preventing DIO and PlGF-/- protection against 
DIO has been inconsistent. It is disappointing that the study of long-term HF feeding 
in PlGF-/- mice (5) has not been replicated. If PlGF plays a role in adipogenesis, it 
appears likely to be via its promotion of angiogenesis/vasculogenesis, rather than via 
the direct promotion of preadipocyte differentiation (64). Regardless, adipose tissue 
production of PlGF may not be restricted to endothelial cells; adipocytes and 
preadipocytes may contribute to its local production and thus the adipogenic 
environment. Therefore, an understanding of the molecular regulation of PlGF in 
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adipocytes and preadipocytes is desirable. The work presented here is a preliminary 
exploration of such PlGF regulation. 
 
1.7 Hypothesis, Objectives and Aims 
 
 
As discussed in detail above, PlGF is under the transcriptional control of FOXO1 in 
HUVEC. The literature also points to other influences on PlGF transcription including 
VEGF signalling via VEGFR-2 and cAMP activation of cAMP response-element 
binding protein (CREB). We therefore hypothesised that: 
 
1.  PlGF is under the trancriptional control of FOXO1 in preadipocytes and 
adipocytes. 
 
2.  PlGF transcription in preadipocytes and adipocytes is promoted by VEGF 
 
and cAMP. 
 
 
 
3.  Given that VEGF has similar biological functions to PlGF, it is subject to 
similar trancriptional influences to PlGF in preadipocytes and adipocytes. 
 
Our principal objectives were: 
 
 
1.  To establish whether PlGF is transcribed and released by murine 
preadipocytes and to gain some insight into the molecular regulation of these 
events. 
 
2.  To establish whether VEGF is transcribed by murine preadipocytes and to gain 
some insight into the molecular regulation of these events. 
 
3.  To optimise the differentiation of an immortalised murine preadipocytes and 
primary murine preadipocytes into adipocytes. 
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We aimed: 
 
 
1.  To characterise, in murine preadipocytes, the transcription and cellular release 
of PlGF in response to oxidative stress, exogenous VEGF/cAMP and FoxO1 
adenoviral transfection. 
 
2.  To determine, in murine preadipocytes, the transcription of VEGF in response 
to oxidative stress, exogenous VEGF/cAMP and FoxO1 adenoviral 
transfection. 
 
3.  To characterise, in murine preadipocytes, the transcription of FoxO1 in 
response to oxidative stress and exogenous VEGF/cAMP. 
 
4.  To optimise the differentiation of immortalised murine preadipocytes and 
primary murine preadipocytes into adipocytes. 
 
Additional work characterising the effect of oxidative stress and insulin treatment on 
the release of PlGF from liver slice cultures was also undertaken. Preparation of 
murine aortic rings was carried out in preparation for work yet to be undertaken in our 
lab. 
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2. Methods 
 
 
All reagents used were from Sigma-Aldrich, St. Louis, MO, USA, unless otherwise 
stated. All cell culture was carried out under sterile conditions in a class II safety 
cabinet. 
 
2.1 Cell Culture 
 
 
2.1.1  Immortalised Murine Preadipocytes 
 
 
Immortalised murine preadipocytes isolated from inguinal fat tissue (IngPA) (see (66)) 
were cultured in T75 cell culture flasks, each containing 15 mL Dulbecco's Modified 
Eagle Medium (DMEM), supplemented with 20% fetal bovine serum (FBS), 100 
μg/mL penicillin/streptomycin and 2 mM L-glutamine. Cells were fed every 2-3 days 
and passaged (1:6) before reaching confluence. 
 
2.1.2  Primary Preadipocytes 
 
 
Primary preadipocytes (PrPA) were isolated from FoxO1,3a,4 floxed mice 
(FoxO1,3,4flox/flox) on an FVB/n background. The inguinal fat pads were exposed by a 
ventral midline incision. The fat pads were removed and pooled in a petri dish 
containing DMEM/F12 (3 mice per pool). The tissue was finely minced between two 
scalpel blades and incubated in 10 mL of 1 mg/mL type 1 collagenase in DMEM/F12 
for 1 hour at 37 °C. The digest was passed through a 1.2 μm filter and the tissue 
retained by the filter was discarded. DMEM/F12 was added to the filtrate up to a total 
volume of 30 mL. The tube was centrifuged at 500 g for 15 minutes. The supernatant 
was discarded and the pellet resuspended in DMEM/F12. Endothelial cell clumps 
were removed by filtering the solutions through a 40 µm filter. The remaining solution 
was centrifuged at 500g for 5 minutes. The supernatant was removed and the pellet 
15  
resuspended in plating medium (DMEM containing 10 % FBS, 100 μg/mL 
penicillin/streptomycin, 2 mM L-glutamine). The cells were plated in T25 culture 
flasks at a density of 2.5x104 cells/cm2. The medium was replaced at 24 hours and 
was subsequently replaced every 2-3 days. The cells were passaged (1:4) before 
they reached confluence (see Table 2.1). 
 
 
 
 
Table 2.1. Cell culture plating details. 
 
Culture Vessel Trypsin/EDTA volume (mL) Medium volume (mL) 
T-75 1 10-15 
T-25 0.5 3-5 
6-well N/A 1-2 
24-well N/A 0.4-0.6 
 
 
 
 
To subculture the cells, the culture media was aspirated and the vessel washed once 
with sterile phosphate buffered saline (PBS). The PBS was aspirated and the cells 
enzymatically dissociated using 1x trypsin. 7 mL of serum-containing medium was 
added to the flask. The contents of the flask were aspirated into a 15 mL falcon tube 
and centrifuged at 300 g, 21 °C for 10 minutes. The supernatant was removed, the 
pellet resuspended in fresh medium and split into culture flasks containing 14 mL of 
prewarmed (37°C) media. The flasks were incubated at 37 °C, 5 % CO2. 
 
2.1.3  Preadipocyte Differentiation 
 
 
Differentiation of preadipocytes was performed using several different protocols 
 
(Table 2.2). 
 
 
IngPA and PrPA were grown to confluence on 6-well/24-well culture plates. 24 hours 
post confluence the medium was changed to induction medium for 24-48 hours (see 
Table 2.2).The medium was subsequently changed to differentiation medium (see 
Table 2.2). The differentiation medium was changed every 48 hours. 
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Table 2.2. Preadipocyte differentiation protocols. 
 
 
Protocol 
Number 
Differentiation medium Induction 
medium 
Induction 
period 
Reason for 
alteration 
1 Growth mediuma 
+ 20 nM Insulin 
+ 1 nM T3 
Differentiation medium 
+ 0.125 mM 
indomethacin 
+ 5 μM 
dexamethasone 
+ 0.5 mM IBMX 
24 hours N/A 
2 As above As above 48 hours Poor differentiation 
at 2 weeks. 
Some protocols 
use 48 hour 
induction. 
3 Growth medium 
+ 172nM Insulin 
As above 48 hours Poor differentiation 
at 2 weeks. 
Some protocols 
use increased 
insulin 
concentration 
without T3. 
a Growth medium = DMEM + 20% Fetal Bovine Serum + 100 μg/mL penicillin/streptomycin+ 2 
mM L-glutamine. Changes from previous protocol in bold. 
 
 
 
 
 
2.2 Adenovirus Transfection of Cells 
 
 
Preadipocytes were grown to confluence on 6-well cell culture plates/chambered cell 
culture slides in their relevant growth media. The cells were transfected with 
adenoviral vectors (1x109 IFU) encoding wild-type FoxO1 (WT-FoxO1), constitutively 
active FoxO1 (CA-FoxO1) and dominant-negative FoxO1 (DN-FoxO1). The 
phosphorylation sites of CA-FoxO1 are mutated, rendering it immune to negative 
regulation by PI3k/Akt (67), DN-FoxO1, retains its DNA binding activity, but lacks a 
transactivation domain (68). On 6-well culture plates, 2 μL adenovirus in 1 mL of 
transfection medium (DMEM, 2 % FBS) was added to each well. 0.5 µL of adenovirus 
in 300 µL of transfection medium was added to each chamber of cell culture slides. At 
24 hours, the transfection medium was changed replaced with growth medium. After 
a further 24 hours the medium was collected and stored at -80 °C. If destined for 
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immunofluorescent examination, cells were incubated in a fixative solution (2 % 
formaldehyde, 2 % glucose, 0.2 % w/v sodium azide in PBS) for 30 minutes, then 
stored under PBS at 4 °C. For quantitative PCR (qPCR) experiments, cells were 
lysed with 150 µL/well of cell lysis solution (Norgen Biotek, ON, Canada). The lysates 
were stored at -80°C. 
 
2.3 Preadipocyte Stimulation 
 
 
IngPA and PrPA were grown to confluence in their respective growth media on 6-well 
and 24-well cell culture plates. Wells were treated in duplicate/triplicate with one of 
the following: H2O2 (1 mM, 200 µM), recombinant VEGF164 (10 ng/mL), forskolin (10 
µM) or cAMP (2.5 mM). At 24 hours the medium was aspirated, retained and stored at 
-80 °C. Cells on 6-well plates were lysed with 150 µL/well of cell lysis solution 
(Norgen Biotek). The lysates were pooled by treatment and stored immediately at -80 
°C. 
 
 
2.4 Immunofluorescence 
 
 
Chambered cell culture slides which had been prepared for immunofluorescence 
were incubated in 100 % methanol for 10 minutes. The wells were washed twice in 
PBS and incubated with 5 % blocking serum (250 µL/well, serum was from same 
species as that in which the secondary antibody was raised) for 20 minutes at room 
temperature (Table 2.3). The serum was aspirated and the cells incubated for 1 hour 
at room temperature in 250 µL/well primary antibody diluted in 1 % BSA/PBS. The 
wells were washed twice in PBS. The slides were incubated at room temperature for 
1 hour in secondary antibody diluted in 1.5 % serum (Table 2.3). The wells were 
washed as before. The plastic chambers were removed and the slides mounted in an 
aqueous mounting medium containing 4',6-diamidino-2-phenylindole (DAPI). Slides 
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were stored in the dark at 4 °C and subsequently imaged using a fluorescence 
 
microscope. 
 
 
 
 
 
 
 
 
Table 2.3. Serum and antibody conditions used for immunofluorescent staining. 
 
Experiment Primary antibody 
(dilution) 
Secondary antibody 
(dilution) 
Blocking 
serum 
1 1° polyclonal rabbit anti- 
FKHK (FoxO1) (Santa 
Cruz Biotechnology) 
(1:50) 
 
Rabbit anti-heme- 
oxygenase-1 (Abcam) 
(1:400) 
Goat anti-rabbit Alexa 
Fluor 594 (Life 
Technologies) 
(1:1000) 
Goat 
2 1° polyclonal rabbit anti- 
FKHK (FoxO1) (Santa 
Cruz Biotechnology) 
(1:50) 
Donkey anti-rabbit FITC 
(Jackson 
ImmunoResearch) 
(1:1000) 
Donkey 
 
 
 
 
 
 
2.5 Enzyme-Linked Immunosorbent Assay – Murine PlGF-2 
 
 
A murine PlGF-2 ELISA kit (R&D systems, Minneapolis, MN, USA) was used 
according to the manufacturer’s instructions. 
 
2.6 Mouse DNA Extraction 
 
 
100 µL of 1x DNA extraction mix (25 mM NaOH, 0.2 mM EDTA) was added to each 
tissue sample. The sample was incubated at 95 °C for 20 minutes, centrifuged briefly 
at 13,000 rpm and 100 µL of 40 mM Tris-HCl was then added. The sample was 
vortexed and transferred to a clean tube. An aliquot of this sample was retained and 
stored at -20 °C, along with any remaining tissue. 20 μL of 3 M NaCl was added to 
the remaining sample. 200 μL isopropanol was then added and the sample 
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centrifuged at 13,000 rpm for 15 minutes at 4 °C. The pellet was washed with 100 μL 
 
70 % EtOH and the sample centrifuged at 13,000 rpm for 5 minutes. The supernatant 
was again discarded and the tube dried by evaporation. The DNA was resuspended 
in 50 μL sterile water and stored at -20 °C. 
 
 
2.7 Reverse transcriptase polymerase chain reaction/agarose gel 
electrophoresis 
 
PCR was carried out on DNA extracted from murine tissues (section 2.6) using a 
DNA polymerase kit (MangoTaq™ DNA Polymerase, Bioline, London, UK) containing 
a reaction buffer suitable for agarose gel electrophoresis. The reaction consisted of 4 
μL 5x reaction buffer, 50 mM  (2 μL) MgCl2, 0.4 µL dNTPs, 0.25 μL Taq polymerase, 
0.4 µL primer mix (Table 2.4), 3 μL of DNA and PCR-grade H2O to 20 µL total 
 
volume. A DNA-free negative control was prepared during each experiment. 
 
 
 
 
Table 2.4. Mouse genotyping primer sequences. 
 
Name Primers (5′→3′) Conditions 
Universal 
Cre 
Universal Cre 5: ACC TGA AGA TGT TCG CGA TTA TCT 
Universal Cre 3:ACC GTC AGT ACG TGA GAT ATC TT 
95°C 5 min 
(95°C 30 sec, 58°C 30 sec, 72°C 60 sec) x 
35 cycles 
72°C 10 min 
FoxO1flox oFK1ckA: CGT TAG AGC AGA GAT GTT CTC ACA TT 
oFK1ckB: CCA GAG TCT TTG TAT CAG GCA AAT AA 
oFK1ckD: CAA GTC CAT TAA TTC AGC ACA TTG A 
95°C 5 min 
(95°C 30 sec, 58°C 30 sec, 72°C 60 sec) x 
35 cycles 
72°C 10 min 
FoxO3flox oFK2ckAnew: GGT TTT CAT GCA GTC CGA GA 
oFK2ckBnew: AAG CAG AAC GTA TGC TTT GA 
oFK2ckDnew: GTG CCA TTC CTT TGG AAA TC 
95°C 5 min 
(95°C 30 sec, 56°C 30 sec, 72°C 60 sec) x 
38 cycles 
72°C 10 min 
 
 
 
A 1-2 % agarose solution in 1xTAE buffer was prepared. 5 µL Midori-green DNA stain 
(Geneflow, Lichfield, UK) was added per 100 mL of agarose solution. An agarose gel 
was poured and the PCR products were added to the wells. The gel was run at 100 V 
for 40 minutes. The DNA bands were visualised by UV illumination at 300 nm. 
 
2.8     RNA Extraction 
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Total RNA was extracted from cell lysates (Sections 2.2, 2.3) using an RNA extraction 
kit (Norgen Biotek).The concentration of eluted RNA was measured using the 
spectrophotometric absorbance of the sample at 260/280 nm. RNA not used 
immediately for cDNA synthesis was stored at -80 °C. 
 
2.9 cDNA Synthesis 
 
 
cDNA was synthesised from total RNA using the Bioline Tetro cDNA synthesis kit 
 
(Bioline, Taunton, MA, USA). The synthesis was carried out in 20 µL reactions (Table 
 
2.5). Once prepared for cDNA synthesis, samples were incubated in a water bath at 
 
45 °C for 1 hour. The temperature was then raised to 55 °C for 30 minutes and 60 °C 
 
for a further 30 minutes. Samples were stored at -20 °C. 
 
 
 
 
Table 2.5. cDNA sythesis reagent volumes per reaction. 
 
Reagent Volume/reaction (µL) 
RNA Volume equivalent to ~5μg 
Primer: Oligo (dT)18 1 
10mM dNTP mix 1 
5x buffer 4 
RNase inhibitor 1 
Tetro reverse transcriptase 1 
DEPC-treated water To 20µL 
 
 
 
 
 
2.10 Quantitative polymerase chain reaction 
 
 
SYBR-Green qPCR was carried out using the SensiMix SYBR Kit (Bioline). cDNA 
was diluted 1:5 in PCR-grade H2O. 15 µL reactions, prepared in duplicate in strip 
tubes (Qiagen, Hilden, Germany) were used (Table 2.6). cDNA-free H2O controls 
were run, in duplicate, for each primer used (Table 2.7). The samples were run on a 
Rotor-Gene 6000 PCR machine (Corbett Life Science, Hilden, Germany). The 
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denaturation step was carried out at 95 °C for 10 minutes. This was followed by 40 
cycles of: (1) denaturation at 95 °C for 10 seconds; (2) annealing at 58 °C for 15 
seconds; (3) extention at 72 °C for 20 seconds and 75 °C for 5 seconds. Finally, a 
melt curve was performed by stepwise (1°C) increase of the temperature from 62 °C 
to 95 °C. The threshold fluorescence was set using a logarithmic view of the curve. It 
was placed in the linear phase of the reaction, above the background signal. Ct 
(cycle threshold) values for each sample were defined the cycle number at which the 
curve crossed the threshold. The relative quantities of RNA were calculated using the 
Pfaffl method (69). Efficiency of the primers used had previously been determined 
using dilutions of target cDNA. 
 
 
 
 
Table 2.6. qPCR reagent volumes per reaction. 
 
Reagent Volume/reaction (µL) 
SensiMix 2x SYBR 7.5 
Primer mix 0.3 
PCR grade H2O 6.2 
Sample/ H2O negative control 1 
 
 
Table 2.7. Murine qPCR primer sequences. 
 
Gene Sequence 
β-actin 5’-GTATGCCTCGGTCGTACCA-3’ 
5’-CTTCTGCATCCTGTCAGCAA-3’ 
PlGF 5'-GAAGTGGAAGTGGTGCCTTT-3' 
5'-CGACTCAGAAGGACACAGGA-3' 
VEGF 5’-GAG TAC CCC GAC GAG ATA 
GAG T-3’ 
5’-GGT GAG GTT TGA TCC GCA 
TGA-3’ 
FoxO ? 
Flt-1 5’-GAG GAG GAT GAG GGT GTC 
TAT AGG T-3’ 
5’-GTG ATC AGC TCC AGG TTT GAC 
TT-3’ 
 
All primers designed in-house and synthesised by MWG Eurofins (Ebersberg, Germany). 
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2.11 Liver Slice Culture 
 
 
Age and sex matched mice with conditional endothelial-cell specific FoxO knockout 
(Tie-2-Cre+ FoxO1,3a,4 [eFoKO] or floxed FoxO1,3a,4 [FoFlox]) mice. The mice were 
sacrificed by cervical dislocation in accordance with Home Office rules. Ear samples 
were retained to confirm genotype. A ventral midline incision was made, the 
peritoneum opened and the liver detached at the hilum and diaphragm. Each liver 
was washed in PBS containing 100 μg/mL penicillin/streptomycin, transferred to a 50 
mL falcon tube containing DMEM and stored on ice. Liver slices were precision-cut 
by Dr. Trish Lalor, transferred to 16-well plates and incubated for 7 hours in 500 
 
µL/well Williams E medium at 37 °C, 5 % CO2. After 7 hours, the old medium was 
aspirated and replaced. The livers were treated in duplicate, with one of the following: 
DMEM only, H2O2, (100 µM/ 500 µM), insulin (3 µg/mL). The livers were incubated at 
37 °C, 5 % CO2 for 20 hours. The supernatants from each well were stored at -80 °C. 
One liver slice per treatment condition was snap frozen in liquid nitrogen. The other 
was weighed and fixed in 3 mL 4% formalin for 1 hour. The formalin was then 
replaced by 3 mL 10% sucrose/PBS solution for 1 hour, 3 mL 20 % sucrose/PBS 
solution for 1 hour and finally 3 mL 30 % sucrose/PBS solution for 1 hour. The 
sections were mounted in OCT compound, frozen in an isopentane bath, transferred 
to liquid nitrogen and stored at -80 °C. 
 
2.12 Preparation of Murine Aortic Rings 
 
 
The thoracic and abdominal cavities of eFoKO/FoFlox mice were exposed and the 
thoracic and abdominal aortas excised (76). The aortic lengths were cleaned of peri- 
vascular tissue under microscopic guidance and cut into even (~1 mm), ringed slices. 
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The slices were stored in DMEM at 4 °C overnight. The DMEM and aortic rings were 
retained and stored at -80 °C. 
 
2.13 Statistical Analysis 
 
 
Given the small sample sizes (N < 3) for most of our experiments, application of tests 
of statistical significance was considered inappropriate. Given more time, larger 
sample sizes would have been employed. The sample size was larger for the liver- 
slice culture experiment. T-tests were employed to determine the statistical 
significance of any mean differences (IBM SPSS Statistics 21). 
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3. Results 
 
 
3.1  Preadipocyte Differentiation 
 
We had intended to also investigate the expression of VEGFs in adipocytes. 
Problems were encountered with the number of IngPA and PrPA undergoing 
differentiation. Clusters lipid-filled cells appeared ~ 7 days post-induction (Fig. 3.1), 
however these clusters did not develop further, even when the protocol was 
amended (Section 2.1.3). When left in culture for greater than 2 weeks, the 
preadipocyte monolayer became too confluent and began to die. Given these 
problems, we focused our investigations on the expression of VEGFs in 
preadipocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Representative image of immortalised inguinal preadipocyte 
differentiation at 6 days post-induction. Arrow indicates cluster of lipid-filled cells. 
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3.2 Preadipocyte FoxO1 Adenovirus Transfection 
 
 
To determine whether FoxO1 can regulate the expression of VEGFs in 
preadipocytes, IngPA and PrPA were infected with adenoviruses encoding FoxO1. 
IngPA transfection of an adenovirus encoding WT FoxO1 resulted in a 74 ± 5.5-fold 
(mean ± SEM) increase in FoxO1 mRNA expression (Fig. 3.2). A 3.7 ± 3.3-fold 
increase in VEGF expression and a 7.2 ± 6.6-fold increase in PlGF expression were 
also observed. Transfection of an adenovirus encoding CA FoxO1 induced no 
obvious alteration in FoxO1 (1.3 ± 0.6), VEGF (2.3 ± 1.7) or PlGF (0.8 ± 0.1) 
expression (Fig. 3.2). An adenovirus encoding DN FoxO1 did not produce dramatic 
changes in FOXO1 (3 ± 1.9) and PlGF (1.2 ± 0.1) expression, although VEGF 
expression increased 6.3 ± 0.6-fold (Fig. 3.2). There was no increase in PlGF 
production compared with uninfected control cells when the corresponding 
supernatants were examined by ELISA (Figure 3.3). 
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Figure 3.2. FoxO1, VEGF and PlGF gene expression in FoxO1-transfected 
immortalised murine inguinal preadipocytes. Preadipocytes were incubated with 
FoxO1 adenoviruses (wild type, dominant negative, constitutively active) for 24 hours. At 
48 hours, the cells were lysed. Total RNA was extracted from the lysates,cDNA was 
synthesised and used in SYBR Green qPCR measurement of FoxO1, VEGF and PlGF 
mRNA expression. Data expressed as mean ± SEM. N=2. 
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Figure 3.3. PlGF-2 secretion in FoxO1-transfected 
immortalised murine inguinal preadipocytes. Preadipocytes 
were incubated with FoxO1 adenoviruses (wild type, dominant 
negative, constitutively active) for 24 hours. The medium was 
then changed. After a further 24 hours, PlGF was measured in 
the medium by ELISA. Data expressed as mean ± SEM. N=2. 
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The same FoxO1 adenoviral transfections were carried out in PrPA cells. WT FoxO1 
induced increases in FoxO1 (9.1-fold), VEGF (2-fold) and PlGF (9.2-fold) expression 
(Fig. 3.4). There were small changes in FoxO1, VEGF and PlGF expression with CA 
and DN FoxO1 transfection (Fig. 3.4). The supernatants from transfected cells 
contained considerably more PlGF-2 (WT = 34.3 pg/mL, CA = 46.3 pg/mL, DN = 31.5 
pg/mL) than an untransfected control (4.4 pg/mL) (Fig. 3.5). Given that these results 
are from a single experiment and the small magnitude of the changes observed, 
caution should be exercised in their interpretation. 
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Figure 3.4. FoxO1, VEGF and PlGF gene expression in FoxO1-transfected primary 
murine preadipocytes. Preadipocytes were incubated with FoxO1 adenoviruses (wild 
type, dominant negative, constitutively active) for 24 hours. At 48 hours the cells were 
lysed. Total RNA was extracted from the lysates,cDNA was synthesised and used in 
SYBR Green qPCR measurement of FoxO1, VEGF and PlGF mRNA expression. N=1. 
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Figure 3.5. Supernatant PlGF-2 concentration in FoxO1- 
transfected primary murine preadipocytes. Preadipocytes 
were incubated with FoxO1 adenoviruses (wild type, dominant 
negative, constitutively active) for 24 hours. The medium was 
then changed. After a further 24 hours, PlGF was measured in 
the medium by ELISA. Data expressed as mean ± SEM. N=1 
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3.3 Immunofluorescent Microscopy 
 
 
IngPA were transfected with adenoviruses encoding WT, DN or CA FoxO1. FoxO1 
localisation and abundance were visualised by immunofluorescent labelling. Time 
constraints and limited equipment access restricted our imaging to the control and 
WT-FoxO1 transfected cells. Considerable background fluorescence can be 
appreciated on the control image, along with some cytoplasmic FoxO1 expression 
(Fig. 3.6). Strong cytoplasmic FoxO1 expression is seen in many of the WT-FoxO1 
transfected cells (Fig. 3.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Representative immunofluorescent microscopy images of control and 
wild-type FoxO1 transfected immortalised murine inguinal preadipocytes. Green = 
FITC-labelled FoxO1, red = DAPI. Magnification = 40x. 
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3.4 Preadipocyte Stimulation 
 
 
To assess whether factors which may influence FoxO1 activity can regulate the 
expression of VEGFs in preadipocytes, such cells were stimulated for 24 hours with 
H2O2, VEGF, cAMP and Forskolin . 
 
Treatment of IngPA with H2O2 (1mM), VEGF, cAMP and Forskolin induced 
considerable increases in FoxO1, VEGF and PlGF expression (Fig. 3.7). However, 
the PlGF-2 concentration of the corresponding supernatants was unaffected (Fig. 
3.8). The same treatments also induced increases in PrPA FoxO1, VEGF and PlGF 
expression, although the magnitude of these changes was not as great as those 
seen in the IngPA line (Fig. 3.9). The PrPA supernatants contained less PlGF-2 than 
their IngPA counterparts (Fig. 3.8, 3.10), and H2O2 and VEGF treatments did appear 
to increase PlGF-2 secretion (Fig. 3.10). 
 
Given the prominent effects of VEGF treatment on gene expression, we confirmed 
expression of VEGFR-1 in both IngPA and PrPA. 
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Figure 3.7. FoxO1, VEGF and TPrlGe aFtgmeennetexpression in treated immortalised 
murine inguinal preadipocytes. Preadipocytes were incubated with one of the 
following: H2O2 (1 mM, 200 µM), recombinant VEGF164 (10 ng/mL), forskolin (10 µM) 
or cAMP (2.5 mM) for 24 hours. The cells were lysed. Total RNA was extracted from 
the lysates,cDNA was synthesised and used in SYBR Green qPCR measurement of 
FoxO1, VEGF and PlGF mRNA expression. Data expressed as mean ± SEM. N=2. 
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Figure 3.8. PlGF-2 release in treated immortalised murine 
inguinal preadipocytes. Preadipocytes were incubated with 
one of the following: H2O2 (1 mM, 200 µM), recombinant 
VEGF164 (10 ng/mL), forskolin (10 µM) or cAMP (2.5 mM) for 
24 hours. The medium was collected and its PlGF 
concentration measured by ELISA. Data expressed as mean ± 
SEM. N=2. 
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Figure 3.9. FoxO1, VEGF and PlGF gene expression in treated primary 
murine preadipocytes. Preadipocytes were incubated with one of the following: 
H2O2 (1 mM, 200 µM), recombinant VEGF164 (10 ng/mL), forskolin (10 µM) or 
cAMP (2.5 mM) for 24 hours. The cells were lysed. Total RNA was extracted from 
the lysates,cDNA was synthesised and used in SYBR Green qPCR measurement 
of FoxO1, VEGF and PlGF mRNA expression. Data expressed as mean ± SEM. 
N=2. 
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Figure 3.10. PlGF-2 release in treated primary murine 
preadipocytes. Preadipocytes were incubated with one of the 
following: H2O2 (1 mM, 200 µM), recombinant VEGF164 (10 
ng/mL), forskolin (10 µM) or cAMP (2.5 mM) for 24 hours. The 
medium was collected and its PlGF concentration measured by 
ELISA. Data expressed as mean ± SEM. N=2. 
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3.5 Mouse Genotyping 
 
 
eFoKO, FoFlox and WT mice were genotyped by RT-PCR using primers deigned to 
identify the FoxO1flox and FoxO3flox genotypes. The floxed products are evident in all 
floxed mice (Fig. 3.11, Fig. 3.12). The WT product was identified in the WT mouse 
samples (Fig. 3.11, Fig. 3.12). The FoxO3 KO products are clearly evident in the 
aortic samples (Fig. 3.12), but not the ear samples from the eFoKO mice. This was 
expected, given the endothelial-specific nature of the knockout. The FoxO1 KO is 
less clear, although some poorly resolved bands may be present in the aortic 
samples from the eFoKO mice (Fig. 3.11). 
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Figure 3.11. RT-PCR for the FoxO1flox genotype. DNA was extracted from murine ear and 
aortic tissue sample. RT-PCR was carried out using primers designed to identify wild-type, 
floxed and knockout FoxO1 sequences. The products were run on an agarose gel and 
visualised by UV illumination at 300nm. - = eFoFlox mice + = eFoKO mice, WT = wild-type 
mice. 
 
 
 
 
 
 
Figure 3.12. RT-PCR for the FoxO3flox  genotype. DNA was extracted from murine ear and 
aortic tissue sample. RT-PCR was carried out using primers designed to identify wild-type, floxed 
and knockout FoxO3 sequences. The products were run on an agarose gel and visualised by UV 
illumination at 300nm. - = eFoFlox mice + = eFoKO mice, WT = wild-type mice. 
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3.6 Liver Slice Culture – PlGF-2 ELISA 
 
 
The liver is an important site of lipid uptake and steatosis is often is often associated 
with the metabolic syndrome/obesity. Precision-cut slices of liver from the FoFlox and 
eFoKO mice were used to assess whether factors that may influence FoxO1 activity 
can regulate the liver-slice secretion of PlGF. 
 
No significant difference in supernatant PlGF concentration existed between the 
untreated FoFlox and eFoKO liver slices (Fig. 3.13). H2O2 (500 μM and 100 μM) 
treatments also produced no effect. However, insulin (3 µg/mL) induced a significant 
increase in PlGF secretion from the eFoKO liver slices (Fig. 3.13). 
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Figure 3.13. Effect of endothelial FoxO knockout and precision-cut liver 
slice stimulation on supernatant PlGF concentration. Liver slices were 
precision-cut and maintained in culture for 20 hours with DMEM only 
(control), H2O2, (100µM/ 500µM) or insulin (3µg/mL). The PlGF 
concentration of each supernatant was measure by ELISA and normalised to 
the liver slice weight. Data presented as mean ± SEM. * p<0.05 by 
independent samples T-test, N.S. = non-significant. eFoFlox = floxed 
FoxO1,3a,4 mice3, n=3; eFoKO = endothelial FoxO1, 3a, 4 knockout, n=3. 
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4. Discussion 
 
 
 
4.1 Preadipocyte FoxO1 Adenovirus Transfection 
 
 
Previous results from our lab have shown that PlGF is under the transcriptional 
control of FoxO1 in HUVEC. We used FoxO1 adenoviral vectors to indicate whether 
this control might be conserved in preadipocytes. WT-FoxO1 transfection was 
successful, with robust increases in FoxO1 mRNA observed in IngPA and PrPA cells. 
Additionally, an increase in cellular FoxO1 was observed by immunofluorescent 
imaging. PlGF expression was observed to increase considerably with WT-FoxO1 
adenoviral transfection. 
 
No increase in PlGF secretion was observed in the WT-FoxO1 transfected IngPA 
cells, despite a clear increase in its mRNA expression. An increase of PlGF in the 
supernatant was seen in all transfected PrPA cells, despite PlGF being upregulated in 
the WT-FoxO1 transfected cells only. Given the small sample size we cannot have 
confidence in the accuracy of these results. They may reflect the influence of post- 
transcriptional events on protein abundance and secretion (70). Quantification of 
cellular PlGF by Western blotting would determine whether the increased PlGF 
mRNA expression is accompanied by an increase in its protein expression. 
 
 
The FoxO1 expression data would suggest that infection of the cells with CA-FoxO1 
and DN-FoxO1 adenoviruses was unsuccessful, visual confirmation by 
immunofluorescent imaging was not possible in the time available. However, the DN- 
FoxO1 adenovirus did induce a ~6-fold increase in IngPA VEGF expression. This was 
not replicated in PrPAs. This may be an anomalous result or artefact of adenoviral 
infection itself. Adenovirus vectors are capable of inducing cellular immune 
responses in vitro. As a case in point, NF-κB activation by adenovirus vectors has 
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been demonstrated (67), furthermore VEGF expression is NF-κB dependent in 
human macrophages (72). 
 
Given the time constraints on this work, the amount of virus used was determined by 
a previously successful multiplicity of infection (MOI) in HUVEC. The viruses used 
had also been stored for some time and their titres may consequently have 
decreased. If definitive further work is to be carried out, the titres of such viruses 
should be checked and the optimal MOI for these cells established. 
 
4.2 Preadipocyte Stimulation 
 
 
In both IngPA and PrPA, 1mM H2O2, VEGF, cAMP and Forskolin induced 
considerable increases in FoxO1, VEGF and PlGF expression. 
 
That H2O2 induces PlGF expression is unsurprising, given that our lab has shown it to 
inhibit PI3k/Akt phosphorylation, facilitating FOXO1 nuclear translocation and binding 
to the PlGF promotor in HUVEC (unpublished work). A complete characterisation of 
this signalling pathway is necessary in preadipocytes; alternative explanations such 
as NF-κB mediated PlGF expression (51) should also be explored. H2O2 also induced 
the upregulation of Foxo1 expression. Little is known about the regulation of Foxo1 
expression despite our extensive knowledge of FOXO1 molecular biology. Recent 
work has suggested that FoxO1 expression is mediated by the transcription factor 
cAMP response element-binding protein (CREB) and its co-activators (73). This 
requires upstream PKA phosphorylation of CREB at Ser133, a phenomenon which 
can be induced by H2O2 (74–76), although some have found H2O2 to inhibit PKA 
activation in adipocytes (77) and fibroblasts (78). Negative regulation of the PI3K/Akt 
pathway by H2O2 would be expected to decrease VEGF expression, yet we found 
that its expression increased (79). Many factors promote the transcription of VEGF, 
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including specificity factor 1 (SP-1) (80). SP-1 is cAMP-dependent, and may 
 
therefore be subject to induction by H2O2 (74–76). These mechanisms warrant further 
investigation. 
 
Forskolin increases intracellular cAMP levels (81,82). Forskolin and cAMP treatment 
may have increased FoxO1 expression via activation of CREB and its co-activators. 
A resulting increase in Foxo1 protein levels could subsequently have promoted PlGF 
expression. CREB may also directly meditate a cAMP-induced increase in PlGF 
expression. In BeWo choriocarcinoma cells, Depoix et al. demonstrated that 
exogenous forskolin and cAMP upregulate PlGF expression and identified two CREs 
in the PlGF promotor region (55). Our results also show that IngPA VEGF was 
induced by cAMP and forskolin. As previously discussed, the VEGF transcription 
factor SP-1 is cAMP dependent and may therefore have medicated the increase in 
VEGF expression. 
 
VEGF treatment increased the expression of FoxO1, PlGF and to a lesser extent, 
VEGF itself. VEGF is known to strongly induce PlGF gene and protein expression via 
VEGFR-2 but not VEGFR-1. VEGFR-1 (and VEGFR-3) signalling appear to inhibit 
PlGF expression. The signal is transduced intracellularly via the MAPK and PKC 
(48,49). Interestingly, unpublished work from our lab has shown that knockdown of 
endogenous VEGF also stimulates PlGF expression in HUVEC, yet inhibition of the 
VEGFR-2 alone does not promote such an increase (49). It is possible that 
knockdown of VEGF causes the loss of inhibitory signalling via VEGFR-1 and 
VEGFR-3 and a subsequent increase in PlGF expression. This serves to illustrate the 
complexity of VEGF-family signalling and the need to characterise such events 
further if they are ultimately to be exploited for therapeutic purposes. 
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VEGF has been shown to negatively regulate FOXO1 activity (83), but little is known 
about its transcriptional influence on FOXO1/FoxO1. VEGF signalling through 
VEGFR-2 promotes Ser133 phosphorylation of CREB in rat neurons and endothelial 
cells (84), which may in turn induce FoxO1 transcription (73). Such cAMP activity 
could explain VEGF promoting its own gene expression, via PKA activation of the 
VEGF transcription factor SP-1. 
 
Little difference in supernatant PlGF concentration is evident between the treated 
IngPA cells and their control. In PrPA cells, H2O2 and VEGF appear to have induced 
an increase in such concentrations. However, the absolute concentrations of PlGF in 
PrPA supernatants are low (<10 pg/mL) and it is impossible to trust the accuracy of 
results derived from 2 experiments. Again, quantification of cellular PlGF would 
illustrate whether the observed increases in PlGF mRNA expression are 
accompanied by an increase in protein expression. 
 
4.3 Preadipocyte Differentiation 
 
 
Differentiation of IngPA and PrPA was disappointing, despite alterations being made 
to the protocol. Such protocols have previously been used on mouse embryonic 
fibroblasts in our lab, with some success. Differentiation was induced at 24 hours 
post-confluence, in order to ensure the cells had undergone post-confluent mitosis. 
This growth arrest is necessary for adipogenesis (85). Our cells displayed 
overlapping growth at 7 days post-confluence and subsequently detached from their 
growth plate, a phenomenon which has also been described by others (86).  Their 
growth arrest may therefore have been poor. This may explain the disappointing 
results obtained. Cao et al. used serum starvation to halt the growth of subconfluent 
3T3-L1 preadipocytes; this facilitated their differentiation (90% adipocyte morphology 
at 19 days) and prevented their detachment (86). Preadipocyte differentiation is more 
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successful in cells from younger rats (87). The mice used in our work were relatively 
old (10 weeks). Younger mice should be used for future isolation of primary 
preadipocytes. 
 
4.4 Mouse Genotyping 
 
 
Genotyping of the eFoKO and FoFlox mice used in the preparation of liver slices for 
culture was largely successful, particularly in the endothelium-rich aortic samples. 
The resolution of the bands depicted in Fig. 3.11 leave something to be desired. It is 
possible that some poorly resolved FoxO1 KO bands are present in the aortic 
samples from the eFoKO mice (Fig. 3.11). The FoxO1 KO bands are only 41 base 
pairs removed from the flox bands, making their resolution difficult. Previous attempts 
by our lab to resolve these bands have failed. Further attempts might be made by 
casting a thinner gel (< 3 mm thick) as this could affect the resolution of these small 
fragments. Reducing the quantity of DNA in each well, and lowering of the voltage 
applied may also improve the resolution. Given the small size of the DNA fragments, 
a polyacrylamide gel may separate them more effectively (88). The genotyping of 
these mice is complicated by the endothelial-specific nature of their genetic 
modification. Isolation and culture of endothelial cells (along with other cell types as a 
control) and their subsequent genotyping – see (89) – might yield better results. 
 
4.5 Liver Slice Culture 
 
 
Culture of precision-cut liver slices from eFoKO and FoFlox mice was carried out in 
order to explore the effect of such KO on hepatic PlGF production. Anti-angiogenic 
treatment attenuates non-alcoholic steatosis (NASH) development, although this 
appears to be a VEGFR-2 mediated effect (33). 
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In untreated livers, eFoKO had no effect on PlGF production, perhaps reflecting the 
relatively small number of endothelial cells compared to other cell types within the 
liver (90). Surprisingly, the PlGF concentration in supernatant (normalised to liver 
slice weight) was significantly greater in insulin-treated eFoKO mice compared to that 
in insulin-treated FoFlox mice. Tsuchiya et al. have shown increased endothelial nitric 
oxide (NO) production in hepatic eFoKO endothelial cells, which causes tyrosine 
nitration of hepatic insulin receptors (InsRs). This prevents tyrosine-induced InsR 
phosphorylation. Insulin treatment further promotes endothelial eNOS expression in 
eFoKO, promoting greater InsR phosphorylation. Consequently, insulin receptor 
substrate-1 (Irs1) and Akt Ser473/Thr308 phosphorylation is impaired, along with 
FoxO1/3a phosphorylation (90). Insulin-induced impairment of FoxO1/3a 
phosphorylation would be expected to promote hepatic PlGF production, possibly 
explaining our results. These findings have important metabolic consequences; 
eFoKO promotes hepatic insulin resistance and a resulting increase in hepatic PlGF 
could conceivably promote maladaptive microvascular changes. The findings also 
illustrate the importance of an integrated approach when assessing the 
consequences of manipulating cellular physiology. 
 
 
4.6 Conclusion 
 
 
This work was intended as a preliminary exploration of the molecular regulation of 
PlGF in murine preadipocytes, given its emerging importance in the metabolic 
syndrome and potential contribution to an adipogenic environment. Secondary 
consideration was given to VEGF. WT-FoxO1 adenoviral transfection was successful 
and in keeping with previous findings from our lab, induced an increase in PlGF 
expression. DN-FoxO1 and CA-FoxO1 transfections were unsuccessful; approaches 
to remedying this have been outlined. H2O2, VEGF, cAMP and forskolin treatment 
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induced increases in FoxO1, VEGF and PlGF expression. Mechanisms which may 
underlie these increases have been discussed. CREB promotion of Foxo1 and PlGF 
expression, along with SP-1 promotion of VEGF expression are of particular interest 
and should be explored further. Increases in PlGF mRNA expression were not 
generally reflected in supernatant PlGF concentrations. Intracellular PlGF 
quantification by Western blotting would give some indication as to whether 
increased mRNA expression is accompanied by enhanced protein expression. 
Surprisingly, eFoKO increased precision-cut liver slice production of PlGF. We failed 
to optimise the differentiation of IngPA and PrPA into adipocytes. It had been hoped 
to generate adipocytes to allow the molecular regulation of PlGF to be explored in 
these cells. Further optimisation of the differentiation protocol (see Section 4.3) will 
allow this work to progress. Given the attractiveness of PlGF as an anti-obesity 
target, further efforts should be made to characterise its adipogenic role and 
molecular regulation in both the vascular and adipose fractions of adipose tissue. 
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